

9



Europäisches Patentamt
European Patent Office
Office européen des brevets

11 Publication number:

0 328 090
A2

08/180, 494 #24 DS
IDS w/attach
1/7/98

12

EUROPEAN PATENT APPLICATION

21 Application number: 89102208.9

51 Int. Cl. 4: C07K 7/20 , A61K 37/43 ,
//C07K99:56,C07K99:54

22 Date of filing: 09.02.89

30 Priority: 10.02.88 US 154681

43 Date of publication of application:
16.08.89 Bulletin 89/33

84 Designated Contracting States:
ES GR

71 Applicant: ABBOTT LABORATORIES

Abbott Park Illinois 60064(US)


72 Inventor: Haviv, Fortuna
1125 Oxford Road
Deerfield, IL 60015(US)
Inventor: Greer, Jonathan
6757 N. Sacramento Avenue
Chicago, IL 60645(US)

74 Representative: Modiano, Guido et al
MODIANO, JOSIF, PISANTY & STAUB
Modiano & Associati Via Meravigli, 16
I-20123 Milan(IT)

54 LHRH analogs.

57 The present invention relates to novel "pseudo" nonapeptide and decapeptide derivatives of LHRH. More particularly the present invention relates to derivatives of LHRH wherein the nitrogen atom of at least one of the amide bonds has been alkylated.

INTESTINAL STABILITY OF LHRH ANALOGS RAT JEJUNUM, IN VITRO



EP 0 328 090 A2

LHRH ANALOGS

Technical Field

The present invention relates to novel "pseudo" nonapeptide and decapeptide analogs of LHRH wherein the nitrogen atom of at least one of the amide bonds is alkylated. The invention also relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds and to the use of such compounds for modulating levels of sex hormones in male or female mammals.

Background Art

Luteinizing Hormone Releasing Hormone, known as LHRH or GnRH, is a decapeptide with the following formula:

(pyro)Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂

LHRH is released from the hypothalamus and binds to a receptor on the pituitary gland, causing the release of LH (Luteinizing Hormone) and FSH (Follicle - Stimulating Hormone). Subsequently, LH and FSH act on the gonads to stimulate the synthesis of steroid sex hormones. The pulsatile release of LHRH, and thereby the release of LH and FSH, controls the reproductive cycle in domestic animals and humans. Acute doses of LHRH agonists increase the levels of LH and steroid sex hormones in both animals and humans. Paradoxically, chronic doses of these agonists suppress the levels of LH and steroid hormones. Consequently, the effect of multiple doses of LHRH agonists is to suppress estrogen formation in the female and suppress testosterone formation in the male. The same effect is observed in both animals and humans after administration of acute or chronic doses of LHRH antagonists. LHRH agonists are currently used or under clinical investigation for the treatment of several hormone dependent diseases such as prostate cancer, prostatic hypertrophy, endometriosis, uterine fibroids, precocious puberty and breast cancer. They have also been used as contraceptives. For a review of LHRH analogs see J. Sandow, et al. in "Hypothalamic Hormones. Chemistry, Physiology, and Clinical Applications", edited by D. Gupta and W. Voeters, p. 307 (1978).

Many biologically active LHRH analogs have been studied in animals and humans. All of them are effective by either intravenous, subcutaneous, or depot administration. Intranasal and intravaginal administrations are effective only at very high doses. All of the reported LHRH analogs show 0.1% to 1% potency following oral administration when compared to intravenous doses. One of the major reasons for this low potency is that these peptides are degraded in the stomach by various proteolytic enzymes before reaching the blood system. It would be desirable to prepare analogs of LHRH that are stable against proteolytic enzymes and are biologically potent after oral administration in animals and humans.

Summary of the Invention

The present invention relates to novel "pseudo" nonapeptide and decapeptide derivatives of LHRH. More particularly the present invention relates to derivatives of LHRH wherein the nitrogen atom of at least one of the amide bonds is alkylated.

Brief Description of the Drawings

Figure 1 is a comparison of the in vitro intestinal stability of (pyro)Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt versus (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt.

Disclosure of the Invention

The compounds of the present invention are of the formula:

A-B-C-D-E-F-G-H-I-J

(I)

1 2 3 4 5 6 7 8 9 10

5 or a pharmaceutically acceptable salt thereof;


wherein A is an amino acyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acetyl-L-prolyl, N-acetyl-D-prolyl, N-acetyl-L- $\delta^{3,4}$ -prolyl, N-acetyl-D- $\delta^{3,4}$ -prolyl, N-acetyl-L-phenylalanyl, N-acetyl-D-phenylalanyl, N-acetyl-L-3-4-chlorophenylalanyl, N-acetyl-D-3-4-chlorophenylalanyl, N-acetyl-L-3-4-fluorophenylalanyl, N-acetyl-D-3-4-fluorophenylalanyl, N-acetyl-L-3-2-naphthylalanyl, N-acetyl-D-3-2-naphthylalanyl, N-acetyl-L-3-4-chlorophenylalanyl, N-acetyl-D-3-4-chlorophenylalanyl, N-acetyl-L-3-4-trifluoromethylphenylalanyl, N-acetyl-D-3-4-trifluoromethylphenylalanyl, N-acetyl-L-tyrosyl, N-acetyl-D-tyrosyl, N-acetyl-L-O-methyl-tyrosyl, N-acetyl-D-O-methyl-tyrosyl, N-acetyl-D-3-2-naphthylalanyl, N-acetyl-L-3-1-naphthylalanyl, N-acetyl-D-3-1-naphthylalanyl, N-acetylsarcosyl, N-acetyl-glycyl, L-N-acetyl-N-methylalanyl, N-acetyl-D-N-methyl-D-alanyl, N-acetyl-L-phenylalanyl, N-acetyl-D-phenylalanyl, N-formylsarcosyl, N-formyl-N-methyl-L-alanyl, N-formyl-N-methylalanyl, 2-N-(ethylaminocarbonyl)-5-N-(ethylamido)glutamyl, N- δ -ethyl-glutamyl, L-prolyl, D-prolyl, L- $\delta^{3,4}$ -prolyl, D- $\delta^{3,4}$ -prolyl, L-phenylalanyl, D-phenylalanyl, L-3-4-chlorophenylalanyl, D-3-4-chlorophenylalanyl, L-3-4-fluorophenylalanyl, D-3-4-fluorophenylalanyl, alpha-methyl-L-3-4-chlorophenylalanyl, alpha-methyl-D-3-4-chlorophenylalanyl, L-3-4-trifluoromethylphenylalanyl, D-3-4-trifluoromethylphenylalanyl, L-tyrosyl, D-tyrosyl, L-O-methyl-tyrosyl, D-O-methyl-tyrosyl, sarcosyl, glycyl, L-N-methylalanyl, N-methyl-D-alanyl, alpha-methyl-L-phenylalanyl, alpha-methyl-D-phenylalanyl, D-phenylalanyl, and L-phenylalanyl;

B is absent or an amino acyl residue selected from the group consisting of L-histidyl, D-histidyl, L-phenylalanyl, D-phenylalanyl, L-3-(2-naphthyl)-alanyl, D-3-(2-naphthyl)-alanyl, L-3-(1-naphthyl)-alanyl, D-3-(1-naphthyl)-alanyl, L-3-(3-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(2-pyridyl)-alanyl, D-3-(2-pyridyl)-alanyl, L-3-(3-pyrazolyl)-alanyl, D-3-(3-pyrazolyl)-alanyl, L-3-(4-chlorophenyl)-alanyl, D-3-(4-chlorophenyl)-alanyl, L-3-(4-fluorophenyl)-alanyl, D-3-(4-fluorophenyl)-alanyl, L-alpha-methyl-3-(4-chlorophenyl)-alanyl, D-alpha-methyl-3-(4-chlorophenyl)-alanyl, (3S)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl, (3R)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl, (2)-N-(ethylaminocarbonyl) (5)-N-(ethylamido)glutamyl, L-3-(2-pyridyl)-alanyl, D-3-(2-pyridyl)-alanyl, L-3-(3-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(3-quinolyl)-alanyl, D-3-(3-quinolyl)-alanyl, N-(R₃₁)-L-phenylalanyl, N-(R₃₁)-D-phenylalanyl, N-(R₃₁)-D-3-4-chlorophenylalanyl, N-(R₃₁)-L-3-4-chlorophenylalanyl, N-(R₃₁)-D-3-4-fluorophenylalanyl, N-(R₃₁)-L-3-4-fluorophenylalanyl, N-(R₃₁)-D-3-4-trifluoromethylphenylalanyl, N-(R₃₁)-L-3-4-trifluoromethylphenylalanyl, N-(R₃₁)-D-O-methyl-tyrosyl, N-(R₃₁)-L-tyrosyl, N-(R₃₁)-D-O-methyl-tyrosyl, N-(R₃₁)-D-tyrosyl, N-(R₃₁)-L-histidyl, N-(R₃₁)-D-histidyl, N-(R₃₁)-D-3-(2-naphthyl)-alanyl, N-(R₃₁)-L-3-(2-naphthyl)-alanyl, N-(R₃₁)-D-3-(1-naphthyl)-alanyl, and N-(R₃₁)-L-3-(1-naphthyl)-alanyl, wherein R₃₁ is methyl, ethyl, propyl or isopropyl;


C is an amino acyl residue selected from the group consisting of L-tryptyl, D-tryptyl, L-phenylalanyl, D-phenylalanyl, alpha-methyl-L-phenylalanyl, alpha-methyl-D-phenylalanyl, L-3-1-naphthylalanyl, D-3-1-naphthylalanyl, L-O-methyl-tyrosyl, D-O-methyl-tyrosyl, L-3-4-chlorophenylalanyl, D-3-4-chlorophenylalanyl, alpha-methyl-L-3-4-chlorophenylalanyl, alpha-methyl-D-3-4-chlorophenylalanyl, L-3-4-trifluoromethylphenylalanyl, D-3-4-trifluoromethylphenylalanyl, L-3-(3-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(3-quinolyl)-alanyl, D-3-(3-quinolyl)-alanyl, L-3-(2-naphthyl)-alanyl, D-3-(2-naphthyl)-alanyl, N-(R₃₂)-D-phenylalanyl, N-(R₃₂)-L-phenylalanyl, N-(R₃₂)-D-tryptyl, N-(R₃₂)-L-tryptyl, N-(R₃₂)-D-3-4-fluorophenylalanyl, N-(R₃₂)-L-3-4-fluorophenylalanyl, N-(R₃₂)-D-3-4-chlorophenylalanyl, N-(R₃₂)-L-3-4-chlorophenylalanyl, N-(R₃₂)-D-3-4-trifluoromethylphenylalanyl, N-(R₃₂)-L-3-4-trifluoromethylphenylalanyl, N-(R₃₂)-D-3-(2-naphthyl)-alanyl, N-(R₃₂)-L-3-(2-naphthyl)-alanyl, N-(R₃₂)-D-3-(1-naphthyl)-alanyl, N-(R₃₂)-L-3-(1-naphthyl)-alanyl, N-(R₃₂)-O-methyl-D-tyrosyl and N-(R₃₂)-O-methyl-L-tyrosyl, wherein R₃₂ is methyl, ethyl, propyl or isopropyl;

D is an amino acyl residue selected from the group consisting of prolyl, L-seryl, O-benzyl-L-seryl, L-alanyl, L-threonyl, N-(R₀)-L-seryl, N-(R₀)-L-seryl(O-benzyl), N-(R₀)-L-alanyl, and N-(R₀)-L-threonyl wherein R₀ is loweralkyl or allyl; or D is -N(Et)CH₂CH(NHMe)C(O)-;

E is an amino acyl residue selected from the group consisting of L-tyrosyl, L-O-methyl-tyrosyl, L-phenylalanyl, N-(R₃₃)-L-tyrosyl, N-(R₃₃)-O-methyl-L-tyrosyl, N-(R₃₃)-L-phenylalanyl and N-(R₃₃)-O-ethyl-L-tyrosyl, wherein R₃₃ is methyl, ethyl, propyl or isopropyl; or E is




10 wherein n is 1 to 4; R₃₀ is methyl, ethyl, propyl or isopropyl; and R₁ is




or -NHR₂ wherein R₂ is hydrogen, loweralkyl, cycloalkyl or R₂₀C(O)- wherein R₂₀ is a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R₂₀ is a substituted phenyl wherein the substituent is selected from methoxy, amino, alkylamino and dialkylamino; or R₁ is -NH(R₃)C(O)NH(R₄) or -NH(R₃)C(NH₂)=NR₄ wherein R₃ and R₄ are independently selected from hydrogen, loweralkyl and cycloalkyl;

25 F is a D-amino acyl residue derived from any of the naturally occurring alpha-amino acids or from synthetic, non-natural alpha-amino acids, including, but not limited to, a D-amino acyl residue of the formula:



35 wherein y is 1 to 3; R₅ is C₁ to C₆ straight or branched chain alkyl, C₃ to C₆ cycloalkyl, phenyl, alkoxy thioalkoxy, hydroxy, C₁ to C₆ straight or branched chain alkyl, C₃ to C₆ cycloalkyl, hydroxy, alkoxy, thioalkoxy, phenyl, 2-naphthyl, N-benzyl-4-imidazolyl, or a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R₅ is -(CH₂)_mR₆ wherein m is 1 to 4 and R₆ is -NH(R')C(O)NH(R'') or -NH(R')C(NH₂)=NR'' wherein R' and R'' are independently selected from hydrogen, loweralkyl and cycloalkyl; or R₆ is




50 or -NHR₇ wherein R₇ is hydrogen, loweralkyl, cycloalkyl or R₆ is R₂₁C(O)- wherein R₂₁ is a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R₂₁ is a substituted phenyl wherein the substituent is selected from methoxy, amino, alkylamino and dialkylamino; R₃₄ is methyl, ethyl, propyl or isopropyl; and R₃₅ and R₃₆ are independently selected from hydrogen and loweralkyl; or F is R₃₇C(O)(CH₂)_zC(O)- wherein z is 1 to 3 and R₃₇ is hydroxy, alkoxy, phenoxy, amino or p-methoxyphenyl;

55 G is an amino acyl residue selected from the group consisting of L-leucyl, L-isoleucyl, N-(R₃₈)-isoleucyl, norleucyl, N-(R₃₈)-norleucyl, L-N-(R₃₈)leucyl, alloisoleucyl, valyl, norvalyl, tyrosyl, tryptyl, 2-aminobutyryl,


(cyclohexyl)-L-alanyl, N-(R₃₈)-L-cyclohexylalanyl, N-(R₃₈)-valyl, phenylalanyl, N-(R₃₈)-phenylalanyl, N-(R₃₈)-tryptyl, N-(R₃₈)-tyrosyl, prolyl, pipecolyl, seryl and N-(R₃₈)-seryl, wherein R₃₈ is methyl, ethyl, propyl or isopropyl; or

F and G taken together are




wherein R₄₇ is hydrogen, loweralkyl, 3-indolylmethyl, 2-naphthylmethyl, benzyl or substituted benzyl wherein the phenyl ring is substituted with a substituent selected from hydroxy and methoxy;

H is an amino acyl residue of the formula:



wherein p is 1 to 4; R₃₉ is methyl, ethyl, propyl or isopropyl; and R₉ is



or -NHR₁₀ wherein R₁₀ is hydrogen, loweralkyl, cycloalkyl or R₂₂C(O)- wherein R₂₂ is a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R₂₂ is a substituted phenyl wherein the substituent is selected from methoxy, amino, alkylamino and dialkylamino; or R₉ is -NH(R₁₁)C(O)NH(R₁₂) or -NH(R₁₁)C(NH₂)=NR₁₂ wherein R₁₁ and R₁₂ are independently selected from hydrogen, loweralkyl and cycloalkyl;

I is an imino acyl or aliphatic amino acyl residue selected from the group consisting of L-prolyl, L-pipecolyl, 3-(loweralkyl)-prolyl, N-methyl-L-alanyl, N-methyl-norvalyl, 1-dihydroisoindole-2-L-carbonyl and thiazolidine-5-L-carbonyl; and

J is 1-pyrrolidiny, 1-piperidiny, 4-morpholiny, or an amino acyl residue selected from D-alanylamine, L-alanylamine, sarcosylamine, N-(R₄₀)-D-alanylamine, N-(R₄₀)-L-alanylamine, N-(R₄₀)-beta-L-alanylamine, N-(R₄₀)-beta-D-alanylamine, L-2-aminobutyrylamine, D-2-aminobutyrylamine, N-(R₄₀)-L-2-aminobutyrylamine, N-(R₄₀)-D-2-aminobutyrylamine, L-serylamine, D-serylamine, N-(R₄₀)-L-serylamine, N-(R₄₀)-D-serylamine, N-(R₄₀)-L-norvalylamine, N-(R₄₀)-D-norvalylamine, L-norvalylamine, D-norvalylamine, wherein R₄₀ is methyl, ethyl, propyl or isopropyl; or J is -NHR₈ or -NHCH₂CONHR₈ wherein R₈ is hydrogen, loweralkyl, cycloalkyl, fluoro substituted loweralkyl or hydroxy substituted loweralkyl;

or J is -NHNH-C(O)-NH-R₁₃ wherein R₁₃ is hydrogen, loweralkyl, cycloalkyl, hydroxy substituted loweralkyl or fluoro substituted loweralkyl; with the proviso that the amide bond between at least one of the pairs of residues A-B, B-C, C-D, D-E, E-F, F-G, G-H, H-I, or I-J is alkylated on the nitrogen atom and with the proviso that the compound is not

(pyro)Glu-His-Trp-Ser-Tyr-Gly-N-Me-Leu-Arg-Pro-Gly-NH₂, (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-N-Me-Leu-Arg-Pro-Gly-NH₂, (pyro)Glu-His-Trp-Ser-Tyr-Gly-N-Me-Leu-Arg-Pro-NH₂ or (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-N-

Me-Leu-Arg-Pro-NH₂.


These compounds exhibit affinity for LHRH receptors. Compounds of the invention which contain D amino acids at positions 1, 2 and 3 or at positions 2 and 3, or which have position 2 deleted are LHRH antagonists. The other compounds of the invention are LHRH agonists.

As set forth above, and for convenience in describing this invention, the conventional abbreviations for the various common amino acids are used as generally accepted in the peptide art as recommended by the IUPAC-IUB Commission on Biochemical Nomenclature, Biochemistry II, 1726 (1972) These represent L-amino acids, with the exception of the achiral amino acid glycine, and with the further exception of any unnatural or natural amino acids which are achiral, or are otherwise designated as D-. All peptide sequences mentioned herein are written according to the generally accepted convention whereby the N-terminal amino acid is on the left and the C-terminal amino acid is on the right.

Other abbreviations which are useful in describing the invention are the following:

Amino acids, protecting groups, reagents	Abbreviation
L-N-(epsilon)-isopropyllysyl	(isp)Lys
2-(pyridyl)-L-alanyl	2-Pal
Arginine	Arg
t-Butoxycarbonyl	Boc
Benzyl	Bzl
Benzyloxycarbonyl	Cbz
N,N'-Dicyclohexylcarbodiimide	DCC
Glycine	Gly
Histidine	His
1-Hydroxybenzotriazole	HOBt
Isoleucine	Ileu
Leucine	Leu
Norleucine	Nleu
Norvaline	Nval
Methionine	Met
Methyl ester	OMe
Benzyl ester	OBzl
Phenylalanine	Phe
Proline	Pro
Pyroglutamic acid	(pyro)Glu
Serine	Ser
Tosyl	Tos
Tryptophan	Trp
Tyrosine	Tyr
N,N'-di-isopropylcarbodiimide	DIC
Dehydro-alanine	DeAla
L-N-methylserine	N-Me-Ser
(2)-N-methyl-3-N-ethyl-diaminopropionic acid	N-Me-N-Et-Dap
(2)-N-ethylureido-(5)-ethylamidoglutamic acid	EtuEtaGlu
L-N-acetylsarcosyl	N-Ac-Sar
L-N-formylsarcosyl	N-Form-Sar
3-(pyridyl)-L-alanyl	3-Pal
3-(pyrazolyl)-L-alanyl	3-Pyral
(3S)-1,2,3,4-tetrahydroquinoline-3-carbonyl	3-Tic
L-N-methyl-O-benzylseryl	N-Me-Ser(OBzl)
L-O-methyltyrosyl	O-Me-Tyr
L-cyclohexylalanyl	Cha
3-(2-naphthyl)-D-alanyl	D-(2)-Nal
3-(1-naphthyl)-L-alanyl	(1)-Nal
4-Dimethylaminopyridine	DMAP
Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate	BOP
Bis(2-oxo-3-oxazolidinyl)phosphine chloride	BOPCl


The sequence of LHRH has been shown to be



5

Nona- and decapeptides in which the amino acid residues at particular places in the sequence have been replaced by other amino acid residues or other moieties are abbreviated by showing the nature of the substitution, superscribed by the location, followed by LHRH as the parent. For example, the sequence

10



15

is represented

[N-Ac-Sar¹-N-Me-Ser⁴-D-(2)-Nal⁶]LHRH; and the sequence (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Trp⁵-Leu-Arg-Pro-NHEt is represented

[N-Me-Ser⁴-D-Trp⁶-Pro⁹-NHEt]LHRH.

20

As used herein, the term "pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the parent compound and do not impart any undesired toxicological effects. Examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acids, naphthalenedisulfonic acids, polygalacturonic acid; (b) salts with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, and the like; or with an organic cation formed from N,N'-dibenzylethylene-diamine or ethylenediamine; or (c) combinations, of (a) and (b), e.g., a zinc tannate salt and the like.

25

The term "loweralkyl" refers to a straight or branched chain saturated hydrocarbon group having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl.

30

The term "alkyl of 1 to 12 carbon atoms" refers to a straight or branched chain radical of 1 to 12 carbon atoms.

35

The term "cycloalkyl" refers to a cyclic saturated hydrocarbon group having from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term "alkoxy" refers to -OR₄₁ wherein R₄₁ is loweralkyl including, but not limited to, methoxy, ethoxy, t-butyloxy and the like.

The term "thioalkoxy" refers to -SR₄₂ wherein R₄₂ is loweralkyl including, but not limited to, -SCH₃, -SCH₂CH₃ and the like.

40

The term "alkylamino" refers to -NHR₄₄ wherein R₄₄ is loweralkyl including, but not limited to, methylamino, ethylamino and the like.

The term "dialkylamino" refers to -NR₄₅R₄₆ wherein R₄₅ and R₄₆ are independently selected from loweralkyl including, but not limited to, dimethylamino, N-methyl-N-ethyl-amino and the like.

Preferred compounds of the invention include:

45

- [N-Me-Ser⁴-D-Trp⁶-Pro⁹NHEt]LHRH;
- [N-Me-Ser⁴-D-Leu⁶-Pro⁹NHEt]LHRH;
- [N-Me-Ser⁴-D-2-Nal⁶]LHRH;
- [N-Me-Ser⁴-D-Trp⁶-N-Me-Leu⁷-Pro⁹NHEt]LHRH;
- [N-Me-Ser⁴-D-Trp⁶-N-Me-Leu⁷-Pro⁹-AzaGly¹⁰]LHRH;
- 50 [N-Me-Ser⁴-D-O-t-butyl-Ser⁶-Pro⁹NHEt]LHRH;
- [N-Me-Ser⁴-D-Arg⁶-Pro⁹NHEt]LHRH;
- [N-Me-Ser⁴-D-Lys⁶-(N-epsilon-isp)-Pro⁹NHEt]LHRH;
- [N-Ac-Sar¹-N-Me-Ser⁴-D-Trp⁶-Pro⁹NHEt]LHRH;
- [N-Ac-Sar¹-N-Me-Ser⁴-D-2-Nal⁶]LHRH;
- 55 [N-Ac-Sar¹-Phe²-N-Me-Ser⁴-D-Trp⁶-Pro⁹NHEt]LHRH;
- [Phe²-N-Me-Ser⁴-D-Trp⁶-Pro⁹NHEt]LHRH;
- [Phe²-N-Me-Ser⁴-D-2-Nal⁶]LHRH;
- [Phe²-N-Me-Ser⁴-D-Arg⁶-Pro⁹NHEt]LHRH;

THIS PAGE BLANK (USPTO)

- [D-4-CI-Phe^{1,2}-D-Trp³-N-Me-Ser⁴-D-Arg⁶-D-Ala¹⁰]LHRH;
 [N-Ac-Sar¹-(2)-N-Me-(3)-N-Et-Dap⁴-D-Trp⁶-Pro³NHET]LHRH;
 [(2)-N-Me-(3)-N-Et-Dap⁴-D-(2)-Nal⁶]LHRH;
 [(2)-N-Me-(3)-N-Et-Dap⁴-D-Trp⁶-Pro³NHET]LHRH;
 5 [(2)-N-Me-(3)-N-Et-Dap⁴-D-Arg⁶-Pro³NHET]LHRH;
 [(2)-N-Me-(3)-N-Et-Dap⁴-D-Leu⁶-Pro³NHET]LHRH;
 [(2)-N-Me-(3)-N-Et-Dap⁴-D-O-t-butyl-Ser⁶-Pro³NHET]LHRH;
 [(2)-N-Me-(3)-N-Et-Dap⁴-D-Trp⁶-N-Me-Leu⁷-Pro³NHET]LHRH;
 [(2)-N-(Ethylaminocarbonyl)-(5)-N-Ethylamido-Glu-N-Me-Ser⁴-D-2-Nal]LHRH;
 10 [N-Me-Ser⁴-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetyl]^{6,7}-Pro³NHET]LHRH;
 [N-Ac-Sar¹-N-Me-Ser⁴-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-isopropylmethylacetyl]^{6,7}-Pro³NHET]LHRH;
 [Phe²-N-Me-Ser⁴-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetyl]^{6,7}-Pro³NHET]LHRH;
 [N-Ac-D-4-CI-Phe¹-D-4-CI-Phe²-D-Trp^{3,6}-N-Me-Ser⁴-D-Ala¹⁰]LHRH;
 [N-Ac-Pro¹-D-CI-Phe²-D-Trp³-N-Me-Ser⁴-D-Arg⁶-D-Ala¹⁰]LHRH;
 15 [N-Me-Phe²-D-Trp⁶-Pro³NHET]LHRH;
 N-Me-Tyr⁵-D-Trp⁶-Pro³NHET]LHRH;
 [N-Me-Trp³-D-Trp⁶-Pro³NHET]LHRH;
 [N-Me-1-Nal³-D-Tyr⁶-Pro³NHET]LHRH;
 [N-Me-D-Leu⁶-Pro³NHET]LHRH;
 20 [D-Trp⁶-N-Me-Arg⁸-Pro³NHET]LHRH
 [D-Trp⁶-Sar¹⁰]LHRH;
 [N-Ac-3,4-dehydro-Pro¹-4-CI-D-Phe²-D-Trp^{3,6}-N-Me-Tyr⁵-D-Ala¹⁰]LHRH;
 [N-Me-Phe²-N-Me-Tyr⁵-D-Trp⁶-Pro³NHET]LHRH;
 [N-Ac-3,4-dehydro-Pro¹-4-CI-D-Phe²-D-Trp³-N-Me-Tyr⁵-D-Arg⁶-N-Me-Leu⁷-D-Ala¹⁰]LHRH;
 25 [N-Ac-D-2-Nal-4-CI-D-Phe²-D-3-Pal-N-Me-Ser⁴-Lys⁵-(N-epsilon-nicotinoyl)-D-Lys⁶-(N-epsilon-nicotinoyl)-Lys⁸-
 (N-epsilon-isopropyl)-D-Ala¹⁰]LHRH;
 [N-Ac-D-2-Nal-4-CI-D-Phe²-D-3-Pal-N-Me-Tyr⁵-D-Lys⁶-(N-epsilon-nicotinoyl)-Lys⁸-(N-epsilon-isopropyl)-D-
 Ala¹⁰]LHRH;
 [N-Ac-D-2-Nal-4-CI-D-Phe²-D-3-Pal-N-Me-Ser⁴-Lys⁵-(N-epsilon-nicotinoyl)-D-Lys⁶-(N-epsilon-pyrazinoyl)-
 30 Lys⁸-(N-epsilon-isopropyl)-D-Ala¹⁰]LHRH;
 [N-Me-Tyr⁵-D-Ser⁶(O-t-butyl)-Pro³NHET]LHRH;
 [N-Me-Tyr⁵-D-Leu⁶-Pro³NHET]LHRH;
 [N-Me-Tyr⁵-D-2-Nal⁶]LHRH;
 [N-Me-D-Trp⁶-Pro³NHET]LHRH;
 35 [N-Me-D-2-Nal⁶]LHRH;
 [N-Me-D-Ser⁶(O-t-butyl)-Pro³NHET]LHRH;
 [N-Me-Phe²-D-2-Nal⁶]LHRH;
 [N-Me-Phe²-D-Leu⁶-Pro³NHET]LHRH;
 [N-Me-Phe²-D-Ser⁶(O-t-butyl)-Pro³NHET]LHRH; and
 40 [N-Me-Tyr⁵-D-His⁶(N-im-Bzl)-Pro³NHET]LHRH.

Effect and Utilities of LHRH Agonists and Antagonists

45 The LHRH agonist and antagonist compounds of the invention are useful for treatment of precocious puberty, prostate cancer, prostatic hypertrophy, endometriosis, uterine fibroids, breast cancer, acne, premenstrual syndrome, polycystic ovary syndrome and diseases which result from excessive gonadal hormone production in either sex. LHRH agonists and antagonists are also useful for controlling reproduction in both females and males. LHRH agonists, when administered in pulses, are useful as fertility
 50 promoters. The LHRH agonist compounds of the invention may also be useful for growth promotion in female animals and for spawning promotion in fish.

In the practice of the method of this invention an effective amount of a compound of the invention or a pharmaceutical composition containing the same is administered to the subject in need of, or desiring, such
 55 treatment. These compounds or compositions may be administered by any of a variety of routes depending upon the specific end use, including orally, parenterally (including subcutaneous, intramuscular and intravenous administration), vaginally (particularly for contraception), rectally, buccally (including sublingually), transdermally or intranasally. The most suitable route in any given case will depend upon the use, particular active ingredient, the subject involved, and the judgment of the medical practitioner. The

THIS PAGE BLANK (USPTO)

compound or composition may also be administered by means of slow-release, depot or implant formulations as described more fully herein below.

In general, to modulate levels of sex hormones in male or female mammals for the uses herein above described, it is expedient to administer the active ingredient in amounts between about 0.01 and 10 mg/kg body weight per day, preferably between about 0.1 and 5.0 mg/kg body weight per day. This administration may be accomplished by a single daily administration, by distribution over several applications or by slow release in order to achieve the most effective results.

The exact dose and regimen for administration of these compounds and compositions will necessarily be dependent upon the needs of the individual subject being treated, the type of treatment, the degree of affliction or need and; of course, the judgment of the medical practitioner. In general, parenteral administration requires lower dosage than other methods of administration which are more dependent upon absorption.

A further aspect of the present invention relates to pharmaceutical compositions containing as active ingredient a compound of the present invention which compositions comprise such compound in admixture with a pharmaceutically acceptable, non-toxic carrier. As mentioned above, such compositions may be prepared for use for parenteral (subcutaneous, intramuscular or intravenous) administration, particularly in the form of liquid solutions or suspensions; for use in vaginal or rectal administration, particularly in semisolid forms such as creams and suppositories; for oral or buccal administration, particularly in the form of tablets or capsules, or intranasally, particularly in the form of powders, nasal drops or aerosols.

The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA., 1970. Formulations for parenteral administration may contain as common excipients sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalens and the like. Formulations for inhalation administration may be solid and contain as excipients, for example, lactose, or may be aqueous or oily solutions for administration in the form of nasal drops. For buccal administration typical excipients include sugars, calcium stearate, magnesium stearate, pregelatinated starch, and the like.

It is particularly desirable to deliver the compounds of the present invention to the subject over prolonged periods of time, for example for periods of one week to one year from a single administration. Various slow release, depot or implant dosage forms may be utilized. For example, a dosage form may contain a pharmaceutically acceptable non-toxic salt of a compound of the invention which has a low degree of solubility in body fluids, for example, (a) an acid addition salt with a polybasic acid such as phosphoric acid, sulfuric acid, citric acid, tartaric acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalene mono- or di-sulfonic acids, polygalacturonic acid, and the like; (b) a salt with a polyvalent metal cation such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium and the like, or with an organic cation formed from e.g., N,N'-dibenzylethylenediamine or ethylenediamine; or (c) combinations of (a) and (b) e.g. a zinc tannate salt. Additionally, the compounds of the present invention or, preferably, a relatively insoluble salt such as those just described, may be formulated in a gel, for example, an aluminum monostearate gel with, e.g. sesame oil, suitable for injection. Particularly preferred salts are zinc salts, zinc tannate salts, pamoate salts, and the like. Another type of slow release depot formulation for injection would contain the compound or salt dispersed or encapsulated in a slow degrading, non-toxic, non-antigenic polymer such as a polylactic acid/polyglycolic acid polymer for example as described in U.S. Patent No. 3,773,919. The compounds of the invention or, preferably, relatively insoluble salts such as those described above may also be formulated in cholesterol matrix pellets, particularly for use in animals. Additional slow release, depot or implant formulations, e.g. liposomes, are well known in the literature. See, for example, Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson ed., Marcel Dekker, Inc., New York, 1978. Particular reference with respect to LHRH type compounds may be found, for example, in U.S. Patent No. 4,010,125.

50

Synthesis of the Peptides

The polypeptides of the present invention may be synthesized by any techniques that are known to those skilled in the art. For solid phase peptide synthesis, a summary of the many techniques may be found in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, 1963 and J Meienhofer, Hormonal Proteins and Peptides, Vol. 2., p.46, Academic Press (New York), 1973. For classical solution synthesis see G. Schroder and K. Lupke, The Peptides, vol. 1, Academic Press (New York), 1965.

In general, these methods comprise the sequential addition of one or more amino acids or suitably protected amino acids to a growing peptide chain. Normally, either the amino or carboxyl group of the first amino acid is protected by a suitable protecting group. The protected or derivatized amino acid can then be either attached to an inert solid support or utilized in solution by adding the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected, under conditions suitable for forming the amide linkage. The protecting group is then removed from this newly added amino acid residue and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining protecting groups (and any solid support) are removed sequentially or concurrently, to afford the final polypeptide. By simple modification of this general procedure, it is possible to add more than one amino acid at a time to a growing chain, for example, by coupling (under conditions which do not racemize chiral centers) a protected tripeptide with a properly protected dipeptide to form, after deprotection, a pentapeptide.

A particularly preferred method of preparing compounds of the present invention involves solid phase peptide synthesis.

In this particularly preferred method the alpha-amino function of the amino acids is protected by an acid or base sensitive group. Such protecting groups should have the properties of being stable to the conditions of peptide linkage formation, while being readily removable without destruction of the growing peptide chain or racemization of any of the chiral centers contained therein. Suitable protecting groups are t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), biphenylisopropylloxycarbonyl, t-amylloxycarbonyl, isobornyloxycarbonyl, (alpha, alpha)-dimethyl-3,5-dimethoxybenzyloxycarbonyl, o-nitrophenylsulfenyl, 2-cyano-t-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl and the like. The t-butyloxycarbonyl (Boc) protecting group is preferred.

Particularly preferred side chain protecting groups are, for arginine: nitro, p-toluenesulfonyl, 4-methoxybenzenesulfonyl, Cbz, Boc and adamantyloxycarbonyl; for tyrosine: benzyl, o-bromobenzyloxycarbonyl, 2,6-dichlorobenzyl, isopropyl, cyclohexyl, cyclopentyl and acetyl; for serine: benzyl and tetrahydropyranyl; for histidine: benzyl, Cbz, p-toluenesulfonyl and 2,4-dinitrophenyl; for tryptophan: formyl.

In the solid phase peptide synthesis method, the C-terminal amino acid is attached to a suitable solid support. Suitable solid supports useful for the above synthesis are those materials which are inert to the reagents and reaction conditions of the stepwise condensation-deprotection reactions, as well as being insoluble in the media used. Suitable solid supports are chloromethylpolystyrene-divinylbenzene polymer, hydroxymethyl-polystyrene-divinylbenzene polymer, and the like. Chloromethyl-polystyrene-1% divinylbenzene polymer is especially preferred. For the special case where the C-terminus of the compound will be glycine, a particularly useful support is the benzhydrylamino-polystyrene-divinylbenzene polymer described by P. Rivaille, et al, *Helv. Chim. Acta.*, 54, 2772 (1971). The coupling to the chloromethyl polystyrene-divinylbenzene type of resin is made by means of the reaction of the alpha-N-protected amino acid, especially the Boc-amino acid, as its cesium, tetramethylammonium, triethylammonium, 1,5-diazabicyclo-[5.4.0]undec-5-ene, or similar salt. The coupling reaction is accomplished in a solvent such as ethanol, acetonitrile, N,N-dimethylformamide (DMF), and the like, with the chloromethyl resin at an elevated temperature, for example between about 40° and 60° C, for from about 12 to 48 hours. Preferred reagents and reaction conditions involve the coupling of an alpha-N-Boc amino acid cesium salt with the resin in DMF at about 50° C for about 24 hours. The alpha-N-Boc-amino acid is attached to the benzhydrylamine resin by means of N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIC) with or without 1-hydroxybenzotriazole (HOBT), benzotriazol-1-yloxy-tris(dimethylamino)phosphonium-hexafluorophosphate (BOP) or bis(2-oxo-3-oxazolidinyl)phosphine chloride (BOPCl), mediated coupling for from about 1 to about 24 hours, preferably about 12 hours at a temperature if between about 10° and 50° C, preferably 25° C in a solvent such as dichloromethane or DMF, preferably dichloromethane. The coupling of the carboxyl group to the N-methyl-Ser(OBzl) attached to the peptide resin requires catalysis by 4-dimethylaminopyridine (DMAP), in addition to the carbodiimide reagent.

The coupling of successive protected amino acids can be carried out in an automatic polypeptide synthesizer as is well known in the art. The removal of the alpha-N-protecting groups may be performed in the presence of, for example, a solution of trifluoroacetic acid in methylene chloride, hydrogen chloride in dioxane, hydrogen chloride in acetic acid, or other strong acid solution, preferably 50% trifluoroacetic acid in dichloromethane at about ambient temperature. Each protected amino acid is preferably introduced in 0.4M concentration and approximately 3.5 molar excess and the coupling may be carried out in dichloromethane, dichloromethane/DMF mixtures, DMF and the like, especially in methylene chloride at about ambient temperature. The coupling agent is normally DCC in dichloromethane but may be N,N'-diisopropylcarbodiimide (DIC) or other carbodiimide either alone or in the presence of HOBT, N-hydroxysuccinimide, other N-hydroxyimides or oximes. Alternately, protected amino acid active ester (e.g. p-

nitrophenyl, pentafluorophenyl and the like) or symmetrical anhydrides may be used.

At the end of the solid phase synthesis the fully protected polypeptide is removed from the resin. When the linkage to the resin support is of the benzyl ester type, cleavage is by means of aminolysis with an alkylamine or fluoroalkylamine for peptides with a proline C-terminus, or by aminolysis with, for example, ammonia/methanol or ammonia/ethanol for peptides with a glycine C-terminus at a temperature between about 10° and 50° C, preferably about 25° C, for between about 12 and 48 hours preferably about 18 hours. Alternatively, the peptide may be removed from the resin by transesterification, e.g., with methanol, followed by aminolysis or by direct transamidation. The protected peptide may be purified at this point by silica gel chromatography or taken to the next step directly. The removal of the side chain protecting groups from the polypeptide is performed by treating the aminolysis product with, for example, anhydrous liquid hydrogen fluoride in the presence of anisole and dimethyl phosphite or other carbonium scavenger, treatment with hydrogen fluoride/pyridine complex, treatment with tris(trifluoroacetyl)boron and trifluoroacetic acid, by reduction with hydrogen and palladium on carbon on polyvinylpyrrolidone, or by reduction with sodium in liquid ammonia. Side chain protecting groups are preferably removed with liquid hydrogen fluoride in the presence of anisole and dimethylphosphite at a temperature between about -10 and +10° C, preferably about 0° C, for between about 15 minutes and 1 hour. The fully deprotected polypeptide is then purified by a sequence of chromatographic steps employing any or all of the following types: ion exchange on a weakly basic resin in the acetate form; hydrophobic adsorption chromatography on underivatized polystyrene-divinylbenzene (for example Amberlite XAD); silica gel adsorption chromatography; ion exchange chromatography on carboxymethylcellulose; partition chromatography, e.g., on Sephadex G-25, LH-20, or countercurrent distribution; high performance liquid chromatography (HPLC), especially reverse phase HPLC on octyl- or octadecylsilyl-silica bonded phase column packing.

If a racemic amino acid is used in the 6 position, the diastereomeric nonapeptide or decapeptide final products are separated, and the desired peptide containing a D-amino acid in the appropriate position is isolated and purified, preferably during the above-described chromatographic process.

The preparation of peptides having C-terminal azaglycine amides is preferably done using classical peptide solution synthesis using known peptide intermediates. This is described in more detail in Example 9.

The details for the preparation of peptides using classical peptide solution synthesis are described in Example 2.

The following examples will serve to further illustrate the preparation of the novel compounds of the invention.

Preparation A

N-(t-Butoxycarbonyl)-N-Methyl-O-Benzyl-L-Serine

Cyclohexylamine Salt

Methyl iodide (227.2 g) was added to a solution of N-Boc-O-benzyl-L-serine (23.68 g) in dry and freshly distilled dimethoxyethane (DME) (370 ml) stirred under nitrogen and cooled to 0° C. Subsequently, sodium hydride (50% oil dispersion) (6.4 g) was added in portions over 15 minutes. The reaction mixture was further stirred at 0-5° C for 22 hours and then decomposed by water, and the organic layer was concentrated. The residue was taken up in water (500 ml) and washed with ether (3x100 ml). The aqueous layer was acidified with cold 1N HCl to pH 3.0, and the oil that separated was extracted into ether (3 X 300 ml). The ethereal layer was washed with cold 1N sodium thiosulfate solution (2 x 150 ml) and sodium chloride solution (2 x 150 ml), dried (Na₂SO₄) and concentrated. The crude product was dissolved in ether (300 ml), and cyclohexylamine (8.3 g) was added. The salt that separated was filtered and dried to give N-(t-butoxycarbonyl)-N-methyl-O-benzyl-L-serine cyclohexylamine salt (CHA), m.p. 134-136° C. $[\alpha]_D^{24}$ -8.6(C 1, EtOH); Anal. for C₂₂H₃₄N₂O₅, Calcd: C, 65.00; H, 8.43; N, 6.89; Found: C, 65.05; H, 8.88; N, 6.91.

Preparation BN-Acetyl-Sarcosine

5

4-Dimethylaminopyridine (3.66 g) was added to a solution of sarcosine (26.7 g) and triethylamine (50 ml) in (1:1) dioxane-water (150 ml) cooled at 0° C. A solution of acetyl chloride (22.37 ml) in dioxane (20 ml) was added dropwise over a period of 30 min. The reaction solution was then stirred at room temperature for 1 hour and subsequently was acidified to pH 3 with cold 50% aqueous HCl. The mixture was extracted three times with ethyl acetate. The extracts were washed with a saturated NaCl solution, dried over Na₂SO₄ and concentrated. The residue was crystallized from ethyl acetate to give N-acetyl-sarcosine, m.p. 135-137° C. Fab Mass spec. m/e 132 (M + H); Anal. for C₅H₉NO₃, Calcd: C, 45.79; H, 6.91; N, 10.68; Found: C, 45.78; H, 7.03; N, 10.64.

Preparation C

20

The following intermediates were prepared according to the literature:

Compound	Reference
L-3-(1-Naphthyl)-alanine	Y. Yabe et al., Chem. Pharm. Bull. <u>24</u> , 3149 (1976)
D-3-(2-Naphthyl)-alanine	J.J. Nestor et al., J. Med. Chem. <u>25</u> , 795 (1982)
D-3-(3-Pyridyl)-alanine	P.N. Rao et al., Int. J. Peptide Protein Res. <u>29</u> , 118 (1987).

30

Example 1

35

(pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt

In the reaction vessel of a Biosearch 9500 Peptide Synthesizer was placed 1.5 g (1.05 mmol) of Boc-Pro-O-Resin (Merrifield resin). Amino acids were added sequentially to this resin according to the following synthetic cycle:

1. Deblocking, to remove the t-Boc group from the alpha-amino function of the peptide, is carried out using a solution of 45% trifluoroacetic acid (TFA), 2.5% anisole, 2.0% dimethyl phosphite, and 50.5% methylene chloride. The resin is prewashed with the deblocking solution previously described for one minute and then the deblocking reaction is run for 20 minutes.

2. Base wash, to remove and neutralize the TFA used for deprotection, is carried out using a solution of 10% N,N-diisopropylethylamine in methylene chloride. The resin is washed with base three times for one minute each time after each deblocking step.

3. Coupling reaction is carried out using a 3.5-fold molar excess of 0.4M DMF solution of a t-Boc protected amino acid derivative along with a 3.5-fold molar excess of 0.4M methylene chloride solution of diisopropylcarbodiimide as activator. The activated amino acid is then coupled to the free alpha amino group of the peptide-resin. The reaction time is as described in the following protocol.

55

4. Wash, each reaction step is followed by three washes of one minute each: one of methylene chloride, one of (1:1) methylene-chloride-DMF, and one of DMF.

Protocol:

The amino acids are coupled to the resin in the following order using the conditions indicated:


Amino Acid	Wash	Coupling	Deprotection
Boc-Arg(Tos)	basewash	two-1 hr	deblock
Boc-Leu	basewash	two-1 hr	deblock
Boc-D-Leu	basewash	two-1 hr	deblock
Boc-Tyr(o-Br-Cbz)	basewash	two-1 hr	deblock
Boc-N-Me-Ser(OBzl)	basewash	two-1 hr	deblock
Boc-N-Formyl-Trp containing 0.1% DMAP	basewash	four-1 hr	deblock
Boc-N-im-CBZ-His	basewash	four-1 hr	deblock
Cbz-p-Glu	basewash	four-1 hr	none


Upon the completion of the synthesis the resin is removed from the reaction vessel and dried in vacuo to give the protected polypeptide resin. The protected peptide is removed from the resin upon treatment at room temperature with anhydrous ethylamine with or without 10% DMF or methanol for 48 hours. The resin beads are filtered and washed with methanol. The filtrate is concentrated in vacuo and the residue is triturated with water to give, after filtration and drying, the protected peptide as a white powder. The protecting groups are finally removed upon treatment at 0 °C for 1 hour with 5 to 10 ml anhydrous liquid HF in the presence of 1 ml of anisole and 0.5 ml of dimethyl phosphite. The HF is evaporated and the residue is dissolved in methanol and concentrated in vacuo. The residue is washed twice with ether and then dissolved in a solution of (1:1:0.1) water:acetonitrile:acetic acid, filtered, and lyophilized to give 0.7 g of the crude product. The crude peptide is purified by high performance liquid chromatography on a 25 cm x 2.5 cm Dynamax C-18 column (25-40 micron) using solvent mixtures in a gradient ranging from 89% H₂O/11% CH₃CN/0.1% TFA to 49% H₂O/51% CH₃CN/0.1% TFA over a period of 50 min, and afterwards changing to 100% CH₃CN/0.1% TFA over a period of 10 min. The flow rate is 15 ml/min and UV detection is at 260 nM. The product is eluted at 33.7 min as a single peak, collected and lyophilized to give pure (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt as the trifluoroacetate salt. Fab (fast atom bombardment) Mass spec. m/e 1296 (M + H)⁺. Amino Acid Anal.: 0.8 Pro; 0.8 Arg; 1.0 Leu; 1.0 Tyr; 1.6 Trp; 1.0 His; 1.0 Glu.

Example 2


(pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt

(pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt was prepared using solution synthesis according to the following scheme:





(h)



(i)

Details of the synthesis are as follows:

(a) Fmoc-N-Me-Ser(O-Bzl)

A suspension of Fmoc-Ser(O-Bzl) (4.16 g), paraformaldehyde (2.0 g), and p-toluenesulfonic acid (0.2 g) in toluene (400 ml) was heated under reflux with azeotropic water removal for 45 min. The solution was cooled, diluted with ethyl acetate (250 ml) and washed three times with 5% aqueous NaHCO₃, dried (Na₂SO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with (8:2) hexane:ethyl acetate to give Fmoc-Ser(O-Bzl)-oxazolidin-4-one as a crystalline product, m.p. 108-109° C. Fab Mass spec. m/e 430(M + H)⁺.

Fmoc-Ser(O-Bzl)-oxazolidin-4-one (3.14 g) was dissolved in chloroform (40 ml) and trifluoroacetic acid (40 ml) and triethylsilane (2.55 g) was added. The solution was stirred at room temperature for 22 hours, then concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with (95:5) methylene chloride:methanol to give Fmoc-N-Me-Ser(O-Bzl)-OH as a colorless oil. Fab Mass spec., m/e 432 (M + H)⁺.

(b) Fmoc-N-Me-Ser(O-Bzl)-Tyr-D-Leu-OEt

To a stirred solution of Tyr-D-Leu-OEt hydrochloride (1.649 g) in DMF (10 ml) cooled to 0° C was added N-ethylmorpholine (0.59 ml) in DMF (1 ml), followed by a solution of Fmoc-N-Me-Ser(O-Bzl)-OH (2.18 g) in DMF (5 ml), followed by a solution of HOBt (0.9315 g) in DMF (5 ml), and followed by a solution of DCC (0.947 g) in DMF (2 ml). The reaction solution was stirred at 0° C for 1 hour and then at room temperature for 4 hours. The solvent was removed in vacuo and the residue was purified by silica gel column chromatography eluting with (95:5) methylene chloride:methanol. The product was obtained as a semisolid. Rf 0.35. Fab Mass spec. m/e 736 (M⁺ + H).

(c) N-Me-Ser(O-Bzl)-Tyr-D-Leu-OEt

A solution of Fmoc-N-Me-Ser(O-Bzl)-Tyr-D-Leu-OEt (1.95 g) and N,N-diisopropylamine (10 ml) in dry and degassed DMF (10 ml) was stirred at room temperature for 2 hours. The solvent and excess reagents were removed in vacuo and the residue was purified by silica gel column chromatography eluting with (95:5) methylene chloride:methanol. The product was obtained as a low melting solid. Rf 0.24. Fab Mass spec., m/e 514 (M + H)⁺. Anal for C₂₈H₃₃N₃O₆, Calcd: C, 65.47; H, 7.65; N, 8.18; Found: C, 65.10; H, 7.77; N, 7.98.

(d) Fmoc-Trp-N-Me-Ser(O-Bzl)-Tyr-D-Leu-OEt

To a stirred solution of N-Me-Ser(O-Bzl)-Tyr-D-Leu-OEt (1.316 g), Fmoc-L-Trp (1.09 g) and benzotriazol-1-yloxytris(dimethylamino) phosphonium hexafluorophosphate (BOP) (1.13 g) in acetonitrile (50 ml) was added triethylamine (0.347 ml). The solution was stirred at room temperature for 5 hours. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate, washed with 5% aqueous NaHCO₃, then with 1N HCl, and finally with saturated aqueous NaCl solution, dried (Na₂SO₄) and

concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with (95:5) methylene chloride:methanol. The product was obtained as a semisolid residue. Rf 0.25. Fab Mass spec., m/e 922 ($M^+ + H$).

5

(e) Trp-N-Me-Ser(O-Bzl)-Tyr-D-Leu-OEt

A solution of Fmoc-Trp-N-Me-Ser(O-Bzl)-Tyr-D-Leu-OEt (0.280 g) in acetonitrile (5 ml) and diethylamine (5 ml) was stirred at room temperature for 1 hour. The solvent and excess reagents were removed in vacuo to give the product as a foamy residue. Fab Mass spec. m/e 700 ($M + 1$)⁺. The product was used in the next step without further purification.

15 (f) Cbz-(pyro)Glu-His-Trp-N-Me-Ser(O-Bzl)-Tyr-D-Leu-OEt

To a solution of Trp-N-Me-Ser(O-Bzl)-Tyr-D-Leu-OEt (0.2665 g) in DMF (5 ml) cooled to 0 °C were added sequentially Cbz-(pyro)Glu-His (0.167 g) in DMF (10 ml), HOBt (0.077 g) in DMF (2 ml), and DCC (0.078 g) in DMF (2 ml). The solution was stirred at 0 °C for 2 hours and then at room temperature overnight. The solvent was removed in vacuo and the residue was purified on a silica gel column eluting with (9:1) methylene chloride:methanol. The product was obtained as a solid. Rf 0.317. Fab Mass spec. m/e 1082 ($M + H$)⁺.

25 (g) (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-OEt

A solution of Cbz-(pyro)Glu-His-Trp-N-Me-Ser(O-Bzl)-Tyr-D-Leu-OEt (0.787 g) in (9:1) DMF-water (15 ml) was hydrogenated overnight under 4 atm. pressure and in the presence of 10% Pd(OH)₂/C (0.79 g). The catalyst was filtered and the filtrate was concentrated in vacuo. The residue was triturated with water to give the desired product as an amorphous solid. Fab Mass spec. m/e 857 ($M + H$)⁺.

35 (h) (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-OH

To a solution of (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-OEt (0.519 g) in (1:1) dioxane-water (16 ml) cooled to 0 °C was added 2N aqueous NaOH (0.6 ml). The resulting solution was stirred at 0 °C for 4 hours, then acidified with 0.1M aqueous HCl to pH 5.0 and lyophilized. Fab Mass spec. of the crude product showed m/e 830 for ($M^+ + H$). The crude product was taken to the next step without any additional purification.

40

(i) (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt

To a solution of Leu-Arg-Pro-NHEt dihydrochloride (0.159 g) in DMF (2 ml) cooled to 0 °C was added N-ethylmorpholine (0.042 ml) in DMF (0.2 ml), followed by sequential additions of (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-OH (0.3 g) in DMF (5 ml), HOBt (0.066 g) in DMF (2 ml), and DCC (0.0677 g) in DMF (2 ml). The resulting solution was stirred at 0 °C for 2 hours and then at room temperature overnight. The solvent was removed in vacuo. The residue was dissolved in (1:9) acetic acid-water and the insoluble material was filtered. The filtrate was lyophilized. The powder obtained was purified by high performance liquid chromatography (HPLC) using a 25 cm x 2.5 cm Dynamax C-18 column (25-40 micron) and solvent mixture gradients ranging from 90% H₂O/10% CH₃CN/0.1% TFA to 49% H₂O/51% CH₃CN/0.1% TFA over a period of 50 mins. The flow rate was 15 ml/min and UV detection was at 260 nm. The product was eluted at 30.4 min, was collected and lyophilized to give pure (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-Arg-Pro-NHEt as the trifluoroacetate salt. Fab Mass spec. m/e 1223 ($M + H$)⁺. Amino Acid Anal. : 0.8 Pro; 0.8 Arg; 1.8 Leu; 1.0 Tyr; 1.0 His; 1.0 Glu.

55

Example 3

(pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-(2)-Nal-Leu-Arg-Pro-Gly-NH₂

Using the same instrument and a program similar to that described in Example 1, (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-(2)-Nal-Leu-Arg-Pro-Gly-NH₂ was prepared starting with 1.5 g (1.12 mmol) of Boc-Gly-O-Resin and coupling the amino acids in the order described in the following protocol:

	<u>Amino Acid</u>	<u>Wash</u>	<u>Coupling</u>	<u>Deprotection</u>
	Boc-Pro	basewash	two-1 hr	deblock
	Boc-Arg(Tos)	basewash	two-1 hr	deblock
15	Boc-Leu	basewash	two-1 hr	deblock
	Boc-D-(2)Nal	basewash	two-1 hr	deblock
	Boc-Tyr-(2-Br-Cbz)	basewash	two-1 hr	deblock
	Boc-N-Me-Ser(OBzl)	basewash	two-1 hr	deblock
	Boc-N-formyl-Trp	basewash	four-1 hr	deblock
20	containing 0.1% DMAP			
	Boc-N-im-Cbz-His	basewash	four-1 hr	deblock
	Cbz-(pyro)Glu	basewash	four-1 hr	none

- 25 The peptide was cleaved from the resin upon treatment with anhydrous liquid ammonia (30 ml) and methanol (5 ml) containing 10% of N,N-dimethylethanolamine at room temperature for 48 hrs. The reaction was worked up as described in Example 1. The protecting groups were removed from the peptide with HF/anisole/dimethylphosphite at 0°C for 1 hour. The obtained crude peptide was purified by high performance liquid chromatography using the same column and solvent gradient described in Example 1.
- 30 The product was eluted at 34.9 minutes as a single peak, was collected and lyophilized to give pure (pyro)-Glu-His-Trp-N-Me-Ser-Tyr-D-(2)Nal-Leu-Arg-Pro-Gly-NH₂ as the trifluoroacetate salt. Fab Mass spec. m/e 1336 (M + H)⁺. Amino Acid Anal.: 1.0 Gly; 0.8 Pro; 0.9 Arg; 1.0 Leu; 1.0 Tyr; 0.9 Trp; 1.0 His; 1.0 Glu.

35 Example 4

Using the method described in Example 1 and substituting the appropriate amino acids, the following compounds with a C-terminal Pro-NHCH₂CH₃ can be synthesized:

- 40 (pyro)glutamyl-phenylalanyl-tryptyl-N-methylseryl-tyrosyl-D-tryptyl-leucyl-arginylprolylethylamide;
 (pyro)glutamyl-histidyl-3-(1-naphthyl)alanyl-N-methylseryl-tyrosyl-D-tryptyl-leucyl-arginylprolylethylamide;
 (pyro)glutamyl-histidyl-tryptyl-N-methylserylarginyl-D-tryptyl-leucyl-arginyl-prolylethylamide;
 N-acetylphenylalanyl-D-3-4-chlorophenylalanyl-tryptyl-N-methylseryl-tyrosyl-D-tyrosyl-leucyl-
 arginylprolylethylamide;
- 45 N-acetyl-3-(2-naphthyl)alanyl-D-3-4-fluorophenylalanyl-tryptyl-N-methylseryl-tyrosyl-D-lysyl-leucyl-arginyl-
 prolylethylamide;
 (pyro)glutamyl-histidyl-tryptyl-N-methylseryltyrosyl-D-lysyl(N-epsilon-isopropyl)-leucyl-
 arginylprolylethylamide;
- 50 (pyro)glutamyl-histidyl-tryptyl-N-methylseryltyrosyl-D-seryl(2-t-butyl)-leucyl-arginyl-prolylethylamide;
 (pyro)glutamyl-histidyl-tryptyl-N-methylseryltyrosyl-D-lysyl(N-epsilon-nicotinoyl)-leucyl-
 arginylprolylethylamide;
- (pyro)glutamyl-alpha-methyl-phenylalanyltryptyl-N-methylseryl-tyrosyl-D-cyclohexylalanyl-leucylarginyl-
 prolylethylamide;
- 55 (pyro)glutamyl-histidyl-tryptyl-N-methylseryltyrosyl-D-lysyl(N-epsilon-pyrazinoyl)-cyclohexylalanylarginyl-
 prolylethylamide;
- N-acetyl-sarcosyl-D-3-4-fluorophenylalanyltryptyl-N-methylseryl-tyrosyl-D-tryptyl-leucyl-lysyl(N-epsilon-
 isopropyl)-prolylethylamide;
- N-acetyl-phenylalanyl-D-3-4-chlorophenylalanyl-D-3-(1-naphthyl)alanyl-N-methylseryl-tyrosyl-D-prolyl-leucyl-

(N-epsilon-isopropyl)-lysyl-prolylethylamide;
 N-acetylsarcosyl-histidyl-3-(1-naphthyl)-alanyl-N-methylseryl-tyrosyl-D-tyrosyl-cyclohexylalanyl-
 arginylpropylethylamide;
 N-acetylsarcosyl-D-phenylalanyl-D-tyrosyl(O-methyl)-N-methylseryl-tyrosyl-D-seryl-leucyl-
 5 arginylpropylethylamide;
 N-acetylsarcosyl-phenylalanyl-3-(1-naphthyl)alanyl-N-methylseryl-tyrosyl-D-seryl(O-t-butyl)-leucyl-arginyl-
 propylethylamide;
 (pyro)glutamyl-phenylalanyl-tryptyl-N-methylseryl-tyrosyl-D-tryptyl-leucyl-lysyl(N-epsilon-isopropyl)-
 prolylethylamide;
 10 (pyro)glutamyl-histidyl-3-(1-naphthyl)alanyl-N-methylseryl-tyrosyl-D-3-(2-naphthyl)alanyl-leucyl-lysyl(N-
 epsilon-isopropyl)-prolylethylamide.

Example 5

15

Using the method described in Example 2 and substituting the appropriate amino acids, the following
 compounds can be prepared:
 (pyro)glutamyl-histidyl-tryptyl-N-methylseryl-tyrosyl-D-seryl(O-t-butyl)-leucyl-arginyl-prolylethylamide;
 20 N-acetyl-sarcosyl-histidyl-3-(1-naphthyl)alanyl-N-methylseryl-tyrosyl-D-tyrosyl-leucyl-lysyl(N-epsilon-
 isopropyl)-prolylethylamide;
 (pyro)glutamyl-D-phenylalanyl-tryptyl-N-methylseryl-tyrosyl-D-cyclohexylalanyl-leucyl-arginyl-
 prolylethylamide.
 N-acetylsarcosyl-histidyl-tryptyl-N-methylseryl-tyrosyl-O-t-butyl-D-seryl-cyclohexylalanyl-lysyl(N-epsilon-
 25 isopropyl)-prolylethylamide;
 N-acetyl-sarcosyl-D-alpha-methyl-phenylalanyl-3-(1-naphthyl)alanyl-N-methylseryl-tyrosyl-O-t-butyl-D-seryl-
 leucyl-arginyl-prolylethylamide;
 N-acetyl-3-(2-naphthyl)alanyl-D-3-4-chlorophenylalanyl-D-tryptyl-N-methyl-seryl-tyrosyl-D-tyrosyl-leucyl-
 arginyl-prolylethylamide;
 30 N-acetylsarcosyl-histidyl-tryptyl-N-methylseryl-lysyl(N-epsilon-pyrazinoyl)-D-lysyl(N-epsilon-nicotinoyl)-
 leucyl-arginyl-prolylethylamide;
 (pyro)glutamyl-histidyl-3-(1-naphthyl)alanyl-N-methylseryl-tyrosyl-D-prolyl-leucyl-arginyl-prolylethylamide;
 N-acetylsarcosyl-histidyl-tryptyl-N-methylseryl-lysyl(N-epsilon-pyrazinoyl)-D-
 cyclohexylalanylcyclohexylalanyl-ornithinyl(N-delta-isopropyl)-prolylethylamide.

35

Example 6

40

(pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Trp-N-Me-Leu-Arg-Pro-NHEt

Using the method described in Example 1, but substituting Boc-Leu with Boc-N-methyl-leucine and
 45 adding 0.1% DMAP to the Boc-N-formyl-D-Trp solution in DMF, (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Trp-N-
 Me-Leu-Arg-Pro-NHEt can be prepared.

Example 7

50

N-Ac-Sar-His-Trp-(3)-N-Et-(2)-N-Me-Dap-Tyr-D-Trp-Leu-Arg-Pro-NHEt

55

Using the method described in Example 1, but substituting the Cbz-(pyro)Glu with N-Ac-Sar and the
 Boc-N-Me-Ser(OBzl) with Boc-N-Me-DeAla, the protected peptide attached to the resin was prepared. Upon
 treatment of this resin first with ethylamine and then with HF, as described in Example 1, the crude product

was obtained. This peptide was purified by high performance liquid chromatography using the same conditions described in Example 1. N-Ac-Sar-His-Trp-(3)-N-Et-(2)-N-Me-Dap-Tyr-D-Trp-Leu-Arg-Pro-NHEt as the trifluoroacetate salt eluted at 31.05 minutes as a single peak, was collected and lyophilized. Fab Mass spec. m/e 1325 ($M^+ + H$). Amino Acid Anal.: 1.0 Pro; 1.0 Arg; 1.0 Leu; 1.7 Trp; 1.0 Tyr; 0.9 His; 1.0 Glu.

Example 8

Using the method described in Example 7 and substituting the appropriate amino acids, the following peptides can be prepared:

(pyro)glutamyl-histidyl-tryptyl-3-N-ethyl-2-N-methyl-2,3-diaminopropionyl-tyrosyl-D-tryptyl-leucyl-arginyl-prolylethylamide;

N-acetylsarcosyl-D-phenylalanyl-D-tryptyl-3-N-ethyl-2-N-methyl-2,3-diaminopropionyl-tyrosyl-D-tyrosyl-leucyl-arginyl-prolylethylamide;


N-acetyl-3 4-chlorophenylalanyl-D-phenylalanyl-3-(1-naphthyl)alanyl-3-N-ethyl-2-N-methyl-2,3-diaminopropionyl-tyrosyl-D-lysyl(N-epsilon-nicotinoyl)-leucyl-arginyl-prolylethylamide.

N-acetyl-3,4-dehydro-prolyl-D-3-4-chlorophenylalanyl-D-tryptyl-3-N-ethyl-2-N-methyl-2,3-diaminopropionyl-tyrosyl-D-lysyl(N-epsilon-picoloyl)-valyl-lysyl(N-epsilon-propyl)-prolylethylamide.

Example 9

(pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Leu-Leu-Arg-Pro-AzaGly-NH₂

This peptide is prepared by classical solution synthesis according to the following scheme:



The synthesis of fragment (1) is described in Example 2 and the synthesis of fragment (2) is described in A.S. Dutta, J. Med. Chem. 21, 1018 (1978). Fragment (2) is converted into (3) by hydrogenolysis and (3) is coupled with (1) using DCC/HOBt. The product is purified by high performance chromatography using conditions similar to those described in Example 1.

Example 10

Using the method of Example 3, but substituting Boc-D-(2)Nal with Boc-D-3-(2-benzimidazolyl)-alanate or with Boc-D-3-(2-benzoxazolyl)-alanate, can provide

N-acetylsarcosyl-phenylalanyl-tryptyl-N-methylseryl-tyrosyl-3-(2-benzimidazolyl)-D-alanyl-leucyl-arginyl-prolylethylamide and

N-acetyl-phenylalanyl-D-3-4-chlorophenylalanyl-D-tryptyl-N-methyl-seryl-tyrosyl-3-(2-benzoxazolyl)-D-alanyl-cyclohexylalanyl-arginyl-prolylethylamide, respectively.

THIS PAGE BLANK (USPTO)

Example 11N-Ac-Sar-D-Phe-D-Trp-N-Me-Ser-Tyr-D-(3)-Pal-Leu-Arg-Pro-NHEt

5

Using the method of Example 1, but substituting Boc-D-Leu with Boc-3-(3-pyridyl)-D-Ala and running the coupling for this acid four times, each time for 5 hours, N-Acetylsarcosyl-D-phenylalanyl-D-tryptyl-N-methyl-
 10 seryl-tyrosyl-D-3-pyridylalanyl-leucyl-arginyl-propylethylamide can be obtained.

Example 12

15

(2)-N-(Ethylaminocarbonyl)-(5)-N-ethylamido-Glu-His-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt

Using the same method and same amino acids described in Example 1, Cbz-(pyro)Glu-His(Cbz)-Trp-(N-formyl)-N-Me-Ser(OBzl)-Tyr(O-2-Br-Cbz)-D-Trp(N-formyl)Leu-Arg(Tos)-Pro-O-Resin was obtained. This pep-
 20 tidoresin was treated with methanol (4 ml) containing 10% dimethylethanolamine and with ethyl amine (30 ml). The mixture was stirred at room temperature for 3 days. The resin was filtered and the filtrate was concentrated in vacuo. The residue was triturated with water. The solid was dried over P₂O₅ for 24 hours to give the protected peptide as a dry white powder. The protecting groups were removed upon treatment at
 25 0° C for 1 hour with anhydrous liquid HF, in the presence of 1 ml of anisole and 0.5 ml of dimethylphosphite. The excess reagents were removed in vacuo and the residue was dissolved in methanol and then concentrated in vacuo. The residue was washed twice with ether and then dissolved in a solution of (1:1:0.1) water: acetonitrile: acetic acid, filtered, and lyophilized to give the crude product. This was purified
 30 by high performance liquid chromatography on a 25 cm x 2.5 cm Dynamax C-18 column (25-40 micron) using the same gradient described in Example 1. The product was eluted at 36.5 min. as a single peak, was collected and lyophilized to give pure (2)-N-(ethylaminocarbonyl)-(5)-N-ethylamido-Glu-His-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt as the trifluoroacetate salt. FAB Mass spec. m/e 1412 (M⁺H)⁺. Amino Acid
 Anal.: 1.0 Pro; 1.2 Arg, 1.0 Leu, 0.9 Tyr, 0.9 Trp, 0.8 His, 0.6 Glu.

35

Example 13(pyro)-Glu-His-Trp-N-Me-Ser-Tyr-6,7-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-Isopropylmethylacetyl]-Arg-Pro-NHEt

(pyro)-Glu-His-Trp-N-Me-Ser-Tyr-6,7-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-Isopropylmethylacetyl]Arg-
 45 Pro-NHEt is prepared according to the following steps:

(a) H-Arg(Tos)-Pro-NHEt

50 The protected dipeptide Arg(Tos)-Pro-NHEt can be prepared by solid phase using Boc-Pro-O-Resin (Merrifield resin), deblocking, and coupling with Boc-Arg(Tos) using the same instrument and the same protocol described in Example 1, and afterwards deblocking the peptide-resin with the deblocking solution which was previously described. The obtained Arg(Tos)Pro-O-Resin is then treated with ethylamine at room temperature for 48 hours. Work up, trituration of the product with water, and drying over P₂O₅ gives H-Arg-
 55 (Tos)-Pro-NHEt.

(b) Boc-[2-(S-3-Amino-2-Oxo-Pyrrolidin-1-yl)-S-2-Isopropylmethylacetic] Acid

THIS PAGE BLANK (USPTO)

Boc-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetic] acid can be synthesized using the procedure described by D.F. Veber and R.M. Freidinger in U.S. Patent No. 4,493,934.

5 (c) Boc-[2-(S-3-Amino-2-Oxo-Pyrrolidin-1-yl)-S-2-Isopropylmethylacetyl]-Arginyl-Prolylethylamide

10 10 mmol of Boc-[2 (S 3 amino-2-oxo-pyrrolidin-1 yl)-S-2-isopropylmethylacetic] acid is dissolved in 70 ml of degassed DMF and cooled to 0 °C under nitrogen. 19 mmol of H-Arg(Tos)-Pro-NHEt, which was previously described, is dissolved in 3 ml of degassed DMF, and cooled. To the acid solution 11 mmol of
10 diphenylphosphorylazide and 11 mmol of triethylamine are added, followed by the pre-cooled peptide solution. The reaction mixture is stirred at 0 °C for 3 hours, then at room temperature overnight. The product is worked-up and purified using silica gel column chromatography and eluted with 70:30:3 chloroform/methanol/aqueous ammonia.

15 (d) [2-(S-3-Amino-2-Oxo-Pyrrolidin-1-yl)-S-2-Isopropylmethylacetyl]-Arginyl(Tos)-Prolylethylamide

Boc-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetyl]-arginyl(Tos)-prolylethylamide, obtained from the previous reaction, is dissolved at 0 °C in trifluoroacetic acid (60 ml) containing 1.5% anisole and 1% dimethylphosphite. The solution is then stirred at room temperature for 30 minutes, and then
20 concentrated in vacuo. The residue is washed twice with ether and dried over P₂O₅ to give [2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetyl]-arginyl-(Tos)-prolylethylamide.

(e) Cbz-(pyro)Glu-His(Cbz)Trp-N-Me-Ser(OBzl)-Tyr-(O-2-Br-Cbz)-NHNH₂

25 Cbz-(pyro)Glu-His(Cbz)-Trp-N-Me-Ser(OBzl)-Tyr-(O-2-Br-Cbz)-O-Resin is synthesized using the solid phase method described in Example 1, but starting with Boc-Tyr(O-2-Br-Cbz)-O-Resin (Merrifield resin), deblocking and coupling in a sequential order with the protected amino acids: Boc-N-Me-Ser(OBzl), Boc-Trp(N-formyl), Boc-His(Cbz), and Cbz-(pyro)Glu. The obtained Cbz-(pyro)Glu-His(Cbz)-Trp(N-formyl)-N-Me-Ser-(OBzl)-Tyr(O-2-Br-Cbz)-O-Resin is treated with anhydrous hydrazine in 10% methanol solution at room
30 temperature for 48 hours. The resin is filtered and the filtrate is concentrated in vacuo. The residue is triturated with ether and dried over P₂O₅ to give Cbz-(pyro)Glu-His(Cbz)-Trp-N-Me-Ser(OBzl)-Tyr(2-Br-Cbz)-NHNH₂.

35 (f) Cbz-(pyro)Glu-His(Cbz)-Trp-N-Me-Ser(OBzl)-Tyr(2-Br-Cbz)-6,7-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetyl]-Arg(Tos)-Pro-NHEt

2.6 mmole of the hydrazide Cbz-(pyro)Glu-His(Cbz)-Trp-N-Me-Ser(OBzl)-Tyr(O-2-Br-Cbz)-NHNH₂ is dissolved in 26 ml of degassed DMF and cooled to -10 °C under nitrogen. To the solution is added 2.4 ml of
40 5.8 M hydrochloric acid/THF. The reaction mixture is cooled to -25 °C and to it is added a (1:19) solution of isoamylinitrite/DMF until a positive starch/KI test reaction is obtained. About 16 ml of solution is required. When TLC shows that no hydrazide remained, the reaction mixture is cooled to -40 °C and to it is added a cold DMF solution (4 ml) of [2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetyl]arginyl(Tos)-prolylethylamide, previously obtained. The pH is raised to 8 with triethylamine. The reaction is stirred at -20 °C
45 for 24 hrs., after which the pH is readjusted to pH 8. Additional peptide is added and the reaction is stirred for additional 24 hrs. at the same temperature. The reaction mixture is concentrated in vacuo. The residue is triturated with water. The solid is filtered and dried over P₂O₅ to give Cbz-(pyro)Glu-His(Cbz)-Trp-N-Me-Ser(OBzl)-Tyr(O-2-Br-Cbz)-6,7-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetyl]-Arg(Tos)-Pro-NHEt.

50 (g) (pyro)Glu-His-Trp-N-Me-Ser-Tyr-6,7-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetyl]-Arg-Pro-NHEt

Cbz-(pyro)Glu-His(Cbz)-Trp-N-Me-Ser(OBzl)-Tyr(O-2-Br-Cbz)-6,7-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetyl]-Arg(Tos)-Pro-NHEt, obtained from the previous experiment, is treated at 0 °C for 1
55 hour with anhydrous hydrogen fluoride (10 ml) in the presence of anisole (1.5 ml) and dimethylphosphite (1 ml). The excess reagents are removed in vacuo. The residue is washed three times with ether, then dissolved in

(1:1)-water-acetonitrile solution (3.0 ml) and lyophilized. The crude product is purified by HPLC to give (pyro)Glu-His-Trp-N-Me-Ser-Tyr-6,7-[2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetyl]-Arg-Pro-NHEt.

Example 14

N-AcSar-His-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt

N-AcSar-His-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt was synthesized using the instrument and the method described in Example 1, but substituting (pyro)Glu with N-AcSar and Boc-D-Leu with Boc-D-Trp-(N-Formyl). The crude product was purified using high performance liquid chromatography on a 25 cm x 2.5 cm Dynamax C-18 column (25-40 micron) using solvent mixtures in a gradient ranging from 89% H₂O/11% CH₃CN/0.1% TFA to 49% H₂O/51% CH₃CN/0.1% TFA over a period of 50 min. The flow rate is 15 ml/min. and UV detection is at 260 nm. The product was eluted at 17.59 minutes as a single peak, collected, and lyophilized to give pure (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt as the trifluoroacetate salt. Fab Mass spec. m/e 1298 (M+H)⁺. Amino Acid Anal.: 1.0 Pro, 1.1 Arg, 1.1 Leu, 1.6 Trp, 1.0 Tyr, 0.9 His.

Example 15

(pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt

(pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt was synthesized using the instrument and the method described in Example 1, but substituting Boc-D-Leu with Boc-D-Trp-(N-Formyl). The crude product was purified using high performance liquid chromatography according to the conditions described above. The product was eluted at 33.7 minutes as a single peak, collected, and lyophilized to give pure (pyro)Glu-His-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt as the trifluoroacetate salt. Fab Mass spec. m/e 1296 (M+H)⁺. Amino Acid Anal.: 1.1 Pro, 1.0 Arg, 1.0 Leu, 1.6 Trp, 1.0 Tyr, 1.0 His, 0.8 Glu.

Example 16

N-AcSar-His-Trp-N-Me-Ser-Tyr-D-2-Nal-Leu-Arg-Pro-Gly-NH₂

N-AcSar-His-Trp-N-Me-Ser-Tyr-D-2-Nal-Leu-Arg-Pro-Gly-NH₂ was synthesized using the instrument and the method described in Example 3, but substituting Cbz-(pyro)Glu with N-AcSar. The crude product was purified using high performance liquid chromatography according to the conditions described above. The product was eluted at 24.5 minutes as a single peak, collected, and lyophilized to give pure N-AcSar-His-Trp-N-Me-Ser-Tyr-D-2-Nal-Leu-Arg-Pro-Gly-NH₂ as the trifluoroacetate salt. Fab Mass spec. m/e 1338 (M+H)⁺. Amino Acid Anal.: 1.0 Gly, 1.1 Pro, 0.9 Arg, 1.0 Leu, 1.0 Tyr, 0.8 Trp, 0.8 His.

Example 17

N-Ac-D-4-Cl-Phe-D-4-Cl-Phe-D-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-D-Ala-NH₂

D-4-Cl-Phe-D-4-Cl-Phe-D-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-D-Ala-NH₂ can be synthesized using the instrument and the method described in Example 3, but substituting Cbz-(pyro)Glu and Boc-His-N-im-Cbz with Boc-D-4-Cl-Phe, substituting Boc-Trp(N-indole-formyl) and Boc-D-2-Nal with Boc-D-Trp(N-indole-formyl), and substituting Boc-Gly-O-Resin with Boc-D-Ala-O-Resin, removing the BOC group from the peptide-resin with TFA and acylating the N-terminus using acetylimidazole. The protected peptide is cleaved from the resin with anhydrous ammonia. Subsequently the protecting groups are cleaved upon treatment with liquid HF at 0 °C for 1 hour in the presence of anisole and dimethylphosphite. The crude product is purified using high performance liquid chromatography to give
 N-Ac-D-4-Cl-Phe-D-4-Cl-Phe-D-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-D-AlaNH₂.

Example 18

Using the method described in Example 17 and substituting with the appropriate amino acids, the following compounds can be synthesized:
 N-Acetyl-3,4-dehydro-prolyl-D-3-4-Cl-phenylalanyl-D-tryptyl-N-methyl-seryl-tyrosyl-D-tryptyl-leucyl-arginyl-prolyl-D-alanylamide;
 N-Acetyl-(delta)^{3,4}-prolyl-D-3-4-F-phenylalanyl-D-2-naphthylalanyl-N-methyl-seryl-tyrosyl-D-2-naphthylalanyl-leucyl-arginyl-prolyl-D-alanylamide;
 N-Acetyl-D-3-4-Cl-phenylalanyl-D-2-naphthylalanyl-D-tryptyl-N-methyl-seryl-tyrosyl-D-arginyl-leucyl-arginyl-prolyl-D-alanylamide;
 N-Acetyl-D-3-4-Cl-phenylalanyl-D-phenylalanyl-D-1-naphthylalanyl-N-methyl-seryl-tyrosyl-D-3-pyridylalanyl-N-methyl-leucyl-arginyl-prolyl-D-alanylamide.
 N-Acetylprolyl-D-3-4-Cl-phenylalanyl-D-tryptyl-N-methyl-seryl-tyrosyl-D-2-naphthylalanylcyclohexylalanylylsyl(N-epsilon-isopropyl)-prolyl-D-alanylamide.

Example 19

(pyro)Glu-N-Me-Phe-Trp-Ser-Tyr-D-Trp-Leu-Arg-ProNH₂

Using the same procedure and protocol described in Example 1 but substituting BOC-N-Me-Phe for BOC-His(N-im-CBZ), BOC-D-Trp(N-indole-formyl) for BOC-D-Leu, BOC-Ser(OBzl) for BOC-N-Me-Ser(OBzl) and adding 0.1% DMAP to the solution of Cbz-p-Glu instead of that of BOC-Trp(N-indole-formyl), and following the same workup as previously described,
 (pyro)Glu-N-Me-Phe-Trp-Ser-Tyr-D-Trp-Leu-Arg-ProNH₂ was obtained as crude product. The compound was purified by HPLC as previously described. The product was eluted at 27.3 minutes as a single peak. Fab Mass spec. m/e 1306 (M + H)⁺. Amino Acid Anal.: 1.0 Pro, 1.1 Arg, 1.0 Leu, 1.6 Trp, 0.9 Tyr, 0.7 Ser, 0.9 Glu.

Example 20

(pyro)Glu-His-Trp-Ser-N-Me-Tyr-D-Trp-Leu-Arg-ProNH₂

Using the same procedure and protocol described in Example 1 but substituting BOC-D-Trp(N-indole-formyl) for BOC-D-Leu, BOC-Ser(OBzl) for BOC-N-Me-Ser(OBzl), BOC-N-Me-Tyr(O-1,6-di-Cl-Bzl) for BOC-Tyr(O-Br-CBz), and adding 0.1% DMAP to the solution of BOC-Ser(OBzl) instead of that of BOC-Trp(N-indole-formyl), and following the same workup as previously described,

(pyro)Glu-His-Trp-Ser-N-Me-Tyr-D-Trp-Leu-Arg-ProNH₂ was obtained as a crude product. The compound was purified by HPLC as previously described. The product was eluted at 25.15 minutes as a single peak. Fab Mass spec. m/e 1296 (M + H)⁺. Amino Acid Anal.: 1.1 Pro, 1.2 Arg, 1.1 Leu, 1.3 Trp, 0.7 Ser, 0.9 His, 0.9 Glu.

Example 21

(pyro)Glu-His-Trp-Ser-N-Me-Tyr-D-Leu-Leu-Arg-ProNH₂

Using the same procedure and protocol described in Example 20 but substituting BOC-D-Leu for BOC-D-Trp(N-indole-formyl), and following the same workup as previously described, (pyro)Glu-His-Trp-Ser-N-Me-Tyr-D-Leu-Leu-Arg-ProNH₂ was obtained as a crude product. The compound was purified by HPLC as previously described. The product was eluted at 16.8 minutes as a single peak. Fab Mass spec. m/e 1223 (M + H)⁺. Amino Acid Anal.: 1.0 pro, 0.9 Arg, 1.5 Leu, 0.6 Ser, 0.9 Trp, 0.8 His, 0.8 Glu.

Example 22

(pyro)Glu-His-Trp-Ser-Tyr-N-Me-D-Leu-Leu-Arg-ProNH₂

Using the same procedure and protocol described in Example 1 but substituting BOC-Ser(OBzl) for BOC-N-Me-Ser(OBzl), BOC-N-Me-D-Leu for BOC-D-Leu and adding 0.1% DMAP to the solution of BOC-Tyr(O-Br-Cbz) instead of that of BOC-Trp(N-indole-formyl), and following the same workup as previously described, (pyro)Glu-His-Trp-Ser-Tyr-N-Me-D-Leu-Leu-Arg-ProNH₂ was obtained as a crude product. The compound was purified by HPLC as previously described. The product was eluted at 34.3 minutes, as a single peak. Fab Mass spec. m/e 1223 (M + H)⁺. Amino Acid Anal.: 1.0 Pro, 0.9 Arg, 0.8 Leu, 0.8 Tyr, 0.7 Ser, 0.7 Trp, 0.9 His, 0.9 Glu.

Example 23

(pyro)Glu-His-Trp-Ser-Tyr-D-Trp-Leu-N-Me-Arg-ProNH₂

Using the same procedure described in Example 1 but substituting BOC-Ser(OBzl) for BOC-N-Me-Ser(OBzl), BOC-D-Trp(N-indole-formyl) for BOC-D-Leu, BOC-N-Me-Arg(Tos) for BOC-Arg(Tos) and adding 0.1% DMAP to the solution if BOC-Leu instead of that of BOC-Trp(N-indole-formyl), and following the same workup as previously described, (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-Leu-N-Me-Arg-ProNH₂ was obtained as a crude product. The compound was purified by HPLC using the same conditions previously described.

Example 24

(pyro)Glu-His-N-Me-Trp-Ser-Tyr-D-Trp-Leu-Arg-ProNH₂

Using the same procedure described in Example 1 but substituting BOC-Ser(OBzl) for BOC-N-Me-Ser(OBzl), BOC-N-Me-Trp(N-indole-formyl) for BOC-Trp(N-indole-formyl), BOC-D-Trp(N-indole-formyl) for BOC-D-Leu, and adding 0.1% DMAP to the solution of BOC-His(N-im-CBZ), and following the same workup as previously described.

(pyro)Glu-His-N-Me-Trp-Ser-Tyr-D-Leu-Arg-ProNH₂ can be obtained and subsequently purified by HPLC using the same conditions previously described.

Example 25

(pyro)Glu-His-N-Me-1-Nal-Ser-Tyr-D-Trp-N-Me-Leu-Arg-ProNH₂

Using the same procedure described in Example 1 but substituting BOC-Ser(OBzl) for BOC-N-Me-Ser(OBzl), BOC-N-Me-1-Nal for BOC-Trp(N-indole-formyl), BOC-D-Trp(N-indole-formyl) for BOC-D-Leu, BOC-N-Me-Leu for BOC-Leu, and adding 0.1% DMAP to the solutions of BOC(N-im-CBZ)-His and BOC-D-Trp(N-indole-formyl) instead of that of BOC-Trp(N-indole-formyl).

(pyro)Glu-His-N-Me-1-Nal-Ser-Tyr-D-Trp-N-Me-Leu-Arg-ProNH₂ can be obtained and subsequently purified by HPLC using the same conditions previously described.

Example 26

N-Ac-3,4-dehydro-Pro-4-Cl-D-Phe-D-Trp-Ser-N-Me-Tyr-D-Trp-Leu-Arg-Pro-D-AlaNH₂

Using the same procedure and protocol described in Example 1, but substituting BOC-Pro-O-Resin (Merrifield resin) with BOC-D-Ala-NH-Resin (4-methyl-benzhydrylamine resin), CBZ-(pyro)-Glu with N-Ac-Pro, BOC-His(N-im-CBz) with BOC-4-Cl-D-Phe, BOC-Trp(N-indole-formyl) and BOC-D-Leu with BOC-D-Trp(N-indole-formyl), BOC-Tyr(O-2-Br-CBZ) with BOC-N-Me-Tyr(O-2,6-di-Cl-Bzl) and adding 0.1% DMAP to the solution of BOC-Ser(OBzl) instead of that of BOC-Trp(N-indole-formyl) and acylating the N-terminus of the peptide on the resin using N-acetylimidazole, the peptide resin

N-Ac-3,4-dehydro-Pro-4-Cl-D-Phe-D-Trp-Ser(OBzl)-N-Me-Tyr-(O-2,6-di-Cl-Bzl)-D-Trp(N-indole-formyl)-Leu-Arg(Tos)-Pro-D-Ala-NH-Resin can be obtained. The peptide is cleaved from the resin upon treatment with HF at 0 ° C for 1h in the presence of 5% anisole and 5% dimethyl phosphite. After work up and HPLC purification,

N-Ac-3,4 dehydro-Pro-4-Cl-D-Phe-D-Trp-Ser-N-Me-Tyr-D-Trp-Leu-Arg-Pro-D-AlaNH₂ can be obtained.

Example 27

N-Ac-Sar-Phe-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-SarNH₂

Using same procedure and protocol described in Example 26, but substituting BOC-D-AlaNH-Resin with BOC-Sar-NH-Resin (4-methyl-benzhydrylamine resin), N-Ac-3,4-dehydro-Pro with CBZ-p-Glu, BOC-4-Cl-D-Phe with BOC-Phe, BOC-D-Trp(N-indole-formyl) at position 3 with BOC-Trp(N-indole-formyl), BOC-Ser(OBzl) with BOC-N-Me-Ser(OBzl) and adding 0.1% DMAP to the solutions of BOC-Trp(N-indole-formyl) and BOC-Pro, after HF cleavage, work-up and HPLC purification, N-Ac-Sar-Phe-Trp-N-Me-Ser-Tyr-D-Trp-Leu-Arg-Pro-SarNH₂ can be obtained.

Example 28

5 N-Ac-Sar-N-Me-His-Trp-Ser-N-Me-Tyr-D-Tyr-Leu-Arg-Pro-NHEt

Using the same protocol and procedure described in Example 1 but substituting BOC-N-Me-His(N-im-CBZ) for BOC-His(N-im-CBZ), BOC-Ser(OBzl) for BOC-N-Me-Ser(OBzl), BOC-N-Me-Tyr(O-2,6-di-Cl-Bzl) for
 10 BOC-Tyr(O-2-Br-CBZ), BOC-D-Tyr(O-2-Br-Cbz) for BOC-D-Leu and adding 0.1% DMAP to the solutions of N-Ac-Sar and BOC-Ser(OBzl) instead of that of BOC-Trp(N-indole-formyl), after work-up and HPLC purification, (pyro)Glu-N-Me-His-Trp-Ser-N-Me-Tyr-D-Tyr-Leu-Arg-Pro-NHEt can be obtained.

Example 29

15 N-Ac-3,4-dehydro-Pro-D-4-Cl-Phe-D-Trp-Ser-N-Me-Tyr-D-Arg-N-Me-Leu-Arg-Pro-D-AlaNH₂

Using the same procedure described in Example 26, but substituting the BOC-D-Trp(N-indole-formyl) at position 6 with BOC-D-Arg(Tos), BOC-Leu with BOC-N-Me-Leu, and adding 0.1% of DMAP to the
 20 solution of BOC-D-Arg(Tos) also, after work-up and HPLC purification, N-Ac-3,4-dehydro-Pro-D-4-Cl-Phe-D-Trp-Ser-N-Me-Tyr-D-Arg-N-Me-Leu-Arg-Pro-D-AlaNH₂ can be obtained.

Example 30

30 (pyro)Glu-N-Me-Phe-Trp-Ser-N-Me-Tyr-D-Trp-Leu-Arg-Pro-SarNH₂

Using the same protocol and procedure described in Example 27 but substituting BOC-N-Me-Phe for
 35 BOC-Phe, BOC-Ser(OBzl) for BOC-N-Me-Ser(OBzl), BOC-N-Me-Tyr(O-2,6-di-Cl-Bzl) for BOC-Tyr(O-2-Br-CBZ), and adding 0.1% of DMAP to the solutions of CBZ-(pyro)Glu, BOC-Ser(OBzl) and BOC-Pro, instead of that of BOC-Trp(N-indole-formyl), following HF cleavage, work-up and HPLC purification, (pyro)Glu-N-Me-Phe-Trp-Ser-N-Me-Tyr-D-Trp-Leu-Arg-Pro-SarNH₂ can be obtained.

Example 31

45 N-Ac-Sar-His-Trp-N-Me-Ser-N-Me-Tyr-D-Trp-Leu-Arg-Pro-NHEt

Using the same protocol and procedure described in Example 1 but substituting N-Ac-Sar for CBZ-
 50 (pyro)Glu, BOC-N-Me-Tyr(O-2,6-di-Cl-Bzl) for BOC-Tyr(O-2-Br-CBZ), BOC-D-Trp(N-indole-formyl) for BOC-D-Leu, and adding 0.1% DMAP to the BOC-N-Me-Ser(OBzl) solution also, after work-up and HPLC purification, N-Ac-Sar-His-Trp-N-Me-Ser-N-Me-Tyr-D-Trp-Leu-Arg-Pro-NHEt can be obtained.

Example 32

55

N-Ac-Sar-3-Tic-Trp-N-Me-Tyr-D-Trp-N-Me-Leu-Leu-Arg-ProNHEt

Using the same protocol and procedure described in Example 21 but substituting N-Ac-Sar for Cbz-(pyro)Glu, BOC-3-Tic for BOC-His(N-im-CBZ), BOC-D-Trp(N-indole-formyl) for BOC-D-Leu, BOC-N-Me-Leu for BOC-Leu, and adding 0.1% DMAP to the solution of BOC-D-Trp(N-indole-formyl) also, after workup and HPLC purification,

N-Ac-Sar-3-Tic-Trp-N-Me-Tyr-D-Trp-N-Me-Leu-Leu-Arg-ProNHEt can be obtained.

10

Example 33

15 N-Ac-D-2-Nal-N-Me-D-4-Cl-Phe-D-3-Pal-Ser-Lys(epsilon-N-nicotinoyl)-D-Lys(N-epsilon-nicotinoyl)-Leu-Lys-(N-epsilon-isocrocy)-Pro-D-AlaNH₂

Using a procedure and a synthetic protocol similar to those described in Example 1 but substituting BOC-D-Ala-NH-Resin (4-methyl-benzylhydramine resin) for BOC-Pro-O-Resin (Merrifield resin) and coupling the amino acids according to the following order and coupling protocol:

#	<u>Amino Acid</u>	<u>Coupling</u>
1	BOC-Pro	two-1h
25	2. BOC-Lys(N-epsilon-isopropyl-N-epsilon-CBZ)	two-1h
	3. BOC-Leu	two-1h
30	4. BOC-D-Lys(N-epsilon-FMOC)	two-1h
	5. BOC-Lys(N-epsilon-FMOC)	two-1h
	6. BOC-3-D-Pal	four-2h
	7. BOC-N-Me-D-4-Cl-Phe	four-1h
35	8. N-Ac-D-2-Nal containing 0.1% DMAP	four-1h

Upon completion of the synthesis the resin is treated with 20% piperidine in CH₂Cl₂ solution for 8 hours to remove the FMOC protecting groups from the two Lys. After several washes with CH₂Cl₂ and drying in vacuo, the peptide on the resin is coupled with nicotinic acid using the peptide synthesizer and the two-1h coupling protocol. Subsequently the peptide is cleaved from the resin with HF at 0°C for 1h in the presence of anisole and dimethylphosphite to give N-Ac-D-2-Nal-N-Me-D-4-Cl-Phe-3-Pal-Ser-Lys-(N-epsilon-nicotinoyl)-D-Lys-(N-epsilon-nicotinoyl)-Leu-Lys-(N-epsilon-isopropyl)-Pro-D-AlaNH₂ as a crude product. The peptide can be purified by HPLC using the conditions previously described.

45

Example 34

50

N-Ac-D-2-Nal-N-Me-D-4-Cl-Phe-D-3-Pal-Ser-Lys(N-epsilon-nicotinoyl)-D-Lys(N-epsilon-nicotinoyl)-Leu-Lys-(N-epsilon-isopropyl)-Pro-SarNH₂

Using the same procedure, protocol, and amino acids as described in Example 33 but substituting BOC-Sar-NH-Resin (4-methyl-benzylhydramine resin) for BOC-D-Ala-NH-Resin and also adding 0.1% DMAP to the solution of BOC-Pro, after work-up and HPLC purification, N-Ac-D-2-Nal-N-Me-D-4-Cl-Phe-D-3-Pal-Ser-Lys-(N-epsilon-nicotinoyl)-D-Lys-(N-epsilon-nicotinoyl)-Leu-Lys-(N-epsilon-isopropyl)-Pro-SarNH₂ can be obtained.

THIS PAGE BLANK (USPTO)

Example 35

5 N-Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-N-Me-Ser-Lys-(N-epsilon-nicotinoyl)-D-Lys-(N-epsilon-nicotinoyl)-Leu-Lys-
(N-epsilon-isopropyl)-Pro-D-AlaNH₂

Using the same procedure, protocol and amino acids as described in Example 33, but substituting
 BOC-D-4-Cl-Phe for BOC-N-Me-D-4-Cl-Phe, BOC-N-Me-Ser(OBzl) for BOC-Ser(OBzl) and adding 0.1%
 10 DMAP only to the solution of BOC-Pal, following workup and HPLC purification, the desired compound can
 be obtained.

Example 36

15

N-Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-Ser-N-Me-Tyr-D-Lys-(N-epsilon-picoloyl)-Leu-Lys-(N-epsilon-isopropyl)-
Pro-D-AlaNH₂

20

Using the same procedure, protocol and amino acids as described in Example 33, but substituting
 BOC-N-Me-Tyr(O-2,6-diCl-Bzl) for BOC-Lys-(N-epsilon-FMOC), adding 0.1% DMAP only to the DMF
 solution of BOC-Ser(OBzl), and at the end coupling with picolinic acid instead of nicotinic acid. Following
 workup and HPLC purification, the desired compound can be obtained.

25

Example 37

30

N-Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-N-Me-Ser-Tyr-D-Lys-(N-epsilon-4-pyrazinoyl)-Leu-Lys-(N-epsilon-
isopropyl)-Pro-D-AlaNH₂

Using the same procedure, protocol and amino acids described in Example 33, but substituting BOC-N-
 35 Me-Ser(OBzl) for BOC-Ser(O-Bzl), adding 0.1% DMAP only to the DMF solution of BOC-D-3-Pal and at the
 end coupling with 4-pyrazinecarboxylic acid instead of nicotinic acid, following workup and HPLC purifica-
 tion, the desired compound can be obtained.

40 Assay Procedures

The biological activities of the compounds of the invention are determined by the following assays:

(a) Receptor Binding. A radioligand receptor binding assay is performed in a similar way to that
 described in the literature (J. Marion et al., Mol. Pharmacol. 19 399 (1981)). [D-Leu⁶-des Gly¹⁰]-LHRH ethyl
 45 amide was radioiodinated by the chloramine-T method and used as the radioligand. Pituitary membranes
 containing LHRH receptors are prepared in batches from quick-frozen rat pituitaries obtained from Hilltop
 Labs. The radioligand (50pM), receptors, and compounds to be tested are coincubated for 2 hours at 4° C.
 Bound ligand is separated from free ligand via centrifugation and aspiration. Compounds are tested at six
 half-log concentration increments, and the negative log of the equilibrium dissociation constant (pK_i) is
 50 calculated from the concentration which displaces 50% of specifically bound radioligand.

(b) In vitro LH Release. This assay has been adopted from the literature (H.A. Jinnah and P.M. Conn,
 Endocrinology 118 2599 (1986)). Rat pituitaries are removed from immature female rats, minced, and
 dissociated with collagenase/hyaluronidase. They are allowed to attach to 48-well microtiter plates for 48-72
 hours, then are exposed to test compounds for 3 hours at 37° C. The medium is assayed for released LH
 55 by RIA (radioimmunoassay). This assay is used to determine quantitatively the potencies of LHRH agonists
 from the negative log of the concentration which produces half-maximal release of LH (pD₂).

For assaying LHRH antagonists, exogenous superagonist [D-Leu⁶-Pro⁹NHEt]LHRH is added. The suppres-

THIS PAGE BLANK (USPTO)

sion of LH release by the antagonist is dose related. The assay determines the potencies of the LHRH antagonists from the negative log of the concentration which produces half-maximum suppression of LH (pA₂).

(c) In vivo LH Release. The compound to be tested is administered to castrated rats intravenously and the serum LH concentration at various time points is measured by RIA. The time integrated LH response is calculated and the dose producing half-maximal LH release (ED₅₀) is reported.

(d) Stability against enzymatic degradation. The intestinal stability of the compounds of the invention was determined using in vitro rat jejunum in a reperfusion system. The fractional mucosal loss was an indicator of the relative rate of degradation of the compounds thirty minutes after introduction of the luminal bath. See Figure 1.

The in vitro and in vivo biological activities of representative compounds are shown below:


Compound #	Receptor Binding pK _i	LH Release pD ₂	ED ₅₀ ug/kg i.v.
Ex. 1	8.93	9.43	7.20
Ex. 3	10.4	11.3	0.129
Ex. 7		9.73	9.64
Ex. 12	8.98	9.31	9.90
Ex. 13	10.42	8.50	
Ex. 14	9.43	9.61	0.39
Ex. 15	10.1	10.1	1.38
Ex. 16	9.24	9.29	
Ex. 20	10.80	10.50	
Ex. 21	9.34	9.57	
Ex. 22	9.16	9.60	
LHRH	8.90	9.27	100
---	10.3	10.14	0.12

--- - [D-Leu⁶-desGly¹⁰]LHRH-Et amide.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

Claims

1. A compound of the formula:



or a pharmaceutically acceptable salt thereof;

wherein A is an amino acyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acetyl-L-prolyl, N-acetyl-D-prolyl, N-acetyl-L-delta^{3,4}-prolyl, N-acetyl-D-delta^{3,4}-prolyl, N-acetyl-L-phenylalanyl, N-acetyl-D-phenylalanyl, N-acetyl-L-3-4-chlorophenylalanyl, N-acetyl-D-3-4-chlorophenylalanyl, N-acetyl-L-3-4-fluorophenylalanyl, N-acetyl-D-3-4-fluorophenylalanyl, N-acetyl-L-3-2-naphthylalanyl, N-acetyl-alpha-methyl-L-3-4-chlorophenylalanyl, N-acetyl-alpha-methyl-D-3-4-chlorophenylalanyl, N-acetyl-L-3-4-trifluoromethylphenylalanyl, N-acetyl-D-3-4-trifluoromethylphenylalanyl, N-acetyl-L-tyrosyl, N-acetyl-D-tyrosyl, N-acetyl-L-O-methyl-tyrosyl, N-acetyl-D-O-methyl-tyrosyl, N-acetyl-D-3-2-naphthylalanyl, N-acetyl-L-3-1-naphthylalanyl, N-acetyl-3-1-naphthylalanyl, N-acetylsarcosyl, N-acetyl-glycyl, L-N-acetyl-N-methylalanyl, N-acetyl-N-methyl-D-alanyl, N-acetyl-alpha-methyl-L-phenylalanyl, N-acetyl-alpha-methyl-D-phenylalanyl, N-acetyl-D-phenylalanyl, N-acetyl-L-phenylalanyl, N-formylsarcosyl, N-formyl-N-methyl-L-alanyl, N-formyl-N-

methylalanyl, 2-N-(ethylaminocarbonyl)-5-N-(ethylamido)glutamyl, N-delta-ethyl-glutamyl, L-prolyl, D-prolyl, L-delta^{3,4}-prolyl, D-delta^{3,4}-prolyl, L-phenylalanyl, D-phenylalanyl, L-3-4-chlorophenylalanyl, D-3-4-chlorophenylalanyl, L-3-4-fluorophenylalanyl, D-3-4-fluorophenylalanyl, alpha-methyl-L-3-4-chlorophenylalanyl, alpha-methyl-D-3-4-chlorophenylalanyl, L-3-4-trifluoromethylphenylalanyl, D-3-4-trifluoromethylphenylalanyl, L-tyrosyl, D-tyrosyl, L-O-methyl-tyrosyl, D-O-methyl-tyrosyl, sarcosyl, glycyl, L-phenylalanyl, and L-phenylalanyl;


B is absent or an amino acyl residue selected from the group consisting of L-histidyl, D-histidyl, L-phenylalanyl, D-phenylalanyl, L-3-(2-naphthyl)-alanyl, D-3-(2-naphthyl)-alanyl, L-3-(1-naphthyl)-alanyl, D-3-(1-naphthyl)-alanyl, L-3-(3-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(3-pyrazolyl)-alanyl, D-3-(3-pyrazolyl)-alanyl, L-3-(4-chlorophenyl)-alanyl, D-3-(4-chlorophenyl)-alanyl, L-3-(4-fluorophenyl)-alanyl, D-3-(4-fluorophenyl)-alanyl, L-alpha-methyl-3-(4-chlorophenyl)-alanyl, D-alpha-methyl-3-(4-chlorophenyl)-alanyl, (3S)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl, (3R)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl, (2)-N-(ethylaminocarbonyl)-(5)-N-(ethylamido)glutamyl, L-3-(2-pyridyl)-alanyl, D-3-(2-pyridyl)-alanyl, L-3-(3-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(3-quinolyl)-alanyl, D-3-(3-quinolyl)-alanyl, N-(R₃₁)-L-phenylalanyl, N-(R₃₁)-D-phenylalanyl, N-(R₃₁)-D-3-4-chlorophenylalanyl, N-(R₃₁)-L-3-4-chlorophenylalanyl, N-(R₃₁)-D-3-fluorophenylalanyl, N-(R₃₁)-L-3-4-fluorophenylalanyl, N-(R₃₁)-L-3-4-trifluoromethylphenylalanyl, N-(R₃₁)-D-3-4-trifluoromethylphenylalanyl, N-(R₃₁)-L-O-methyltyrosyl, N-(R₃₁)-D-O-methyl-tyrosyl, N-(R₃₁)-L-3-(2-naphthyl)-alanyl, N-(R₃₁)-D-3-(2-naphthyl)-alanyl, N-(R₃₁)-L-histidyl, N-(R₃₁)-D-histidyl, N-(R₃₁)-L-3-(1-naphthyl)-alanyl, N-(R₃₁)-D-3-(1-naphthyl)-alanyl, and N-(R₃₁)-L-3-(1-naphthyl)-alanyl, wherein R₃₁ is methyl, ethyl, propyl or isopropyl;

C is an amino acyl residue selected from the group consisting of L-tryptyl, D-tryptyl, L-phenylalanyl, D-phenylalanyl, alpha-methyl-L-phenylalanyl, L-3-1-naphthylalanyl, D-3-1-naphthylalanyl, L-O-methyltyrosyl, D-O-methyltyrosyl, L-3-4-chlorophenylalanyl, D-3-4-chlorophenylalanyl, alpha-methyl-L-3-4-chlorophenylalanyl, alpha-methyl-D-3-4-chlorophenylalanyl, L-3-4-trifluoromethylphenylalanyl, D-3-4-trifluoromethylphenylalanyl, L-3-(3-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(3-quinolyl)-alanyl, D-3-(3-quinolyl)-alanyl, L-3-(2-naphthyl)-alanyl, D-3-(2-naphthyl)-alanyl, N-(R₃₂)-D-phenylalanyl, N-(R₃₂)-L-phenylalanyl, N-(R₃₂)-D-tryptyl, N-(R₃₂)-L-tryptyl, N-(R₃₂)-D-3-4-fluorophenylalanyl, N-(R₃₂)-L-3-4-fluorophenylalanyl, N-(R₃₂)-D-3-4-chlorophenylalanyl, N-(R₃₂)-L-3-4-chlorophenylalanyl, N-(R₃₂)-D-3-4-trifluoromethylphenylalanyl, N-(R₃₂)-L-3-4-trifluoromethylphenylalanyl, N-(R₃₂)-D-3-(2-naphthyl)-alanyl, N-(R₃₂)-L-3-(2-naphthyl)-alanyl, N-(R₃₂)-D-3-(1-naphthyl)-alanyl, N-(R₃₂)-L-3-(1-naphthyl)-alanyl, N-(R₃₂)-O-methyl-D-tyrosyl and N-(R₃₂)-O-methyl-L-tyrosyl, wherein R₃₂ is methyl, ethyl, propyl or isopropyl;


D is an amino acyl residue selected from the group consisting of prolyl, L-seryl, O-benzyl-L-seryl, L-alanyl, L-threonyl, N-(R₀)-L-seryl, N-(R₀)-L-seryl(O-benzyl), N-(R₀)-L-alanyl, and N-(R₀)-L-threonyl wherein R₀ is loweralkyl or allyl;

or D is -N(Et)CH₂CH(NHMe)C(O)-;

E is an amino acyl residue selected from the group consisting of L-tyrosyl, L-O-methyl-tyrosyl, L-phenylalanyl, N-(R₃₃)-L-tyrosyl, N-(R₃₃)-O-methyl-L-tyrosyl, N-(R₃₃)-L-phenylalanyl and N-(R₃₃)-O-ethyl-L-tyrosyl, wherein R₃₃ is methyl, ethyl, propyl or isopropyl; or E is



wherein n is 1 to 4; R₃₀ is methyl, ethyl, propyl or isopropyl; and R₁ is




or -NHR₂ wherein R₂ is hydrogen, loweralkyl, cycloalkyl or R₂₀C(O)- wherein R₂₀ is a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic

ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R_{20} is a substituted phenyl wherein the substituent is selected from methoxy, amino, alkylamino and dialkylamino; or R_1 is $-NH(R_3)C(O)NH(R_4)$ or $-NH(R_3)C(NH_2)=NR_4$ wherein R_3 and R_4 are independently selected from hydrogen, loweralkyl and cycloalkyl;

5 F is a D-amino acyl residue derived from any of the naturally occurring alpha-amino acids or from synthetic, non-natural alpha-amino acids;

G is an amino acyl residue selected from the group consisting of L-leucyl, L-isoleucyl, N-(R_{38})-isoleucyl, norleucyl, N-(R_{38})-norleucyl, L-N-(R_{38})leucyl, alloisoleucyl, valyl norvalyl, tyrosyl, tryptyl, 2-aminobutyryl (cyclohexyl)-L-alanyl, N-(R_{38})-L-cyclohexylalanyl, N-(R_{38})-valyl, phenylalanyl, N-(R_{38})-phenylalanyl, N-(R_{38})-tryptyl, N-(R_{38})-tyrosyl, prolyl, pipecolyl, seryl and N-(R_{38})-seryl, wherein R_{38} is methyl, ethyl, propyl or isopropyl; or


F and G taken together are




wherein R_{47} is hydrogen, loweralkyl, 3-indolylmethyl, 2-naphthylmethyl, benzyl or substituted benzyl

25 wherein the phenyl ring is substituted with a substituent selected from hydroxy and methoxy;

H is an amino acyl residue of the formula:



wherein p is 1 to 4; R_{39} is methyl, ethyl, propyl or isopropyl; and R_9 is



45 or $-NHR_{10}$ wherein R_{10} is hydrogen, loweralkyl, cycloalkyl or $R_{22}C(O)-$ wherein R_{22} is a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R_9 is $-NH(R_{11})C(O)NH(R_{12})$ or $-NH(R_{11})C(NH_2)=NR_{12}$ wherein R_{11} and

50 R_{12} are independently selected from hydrogen, loweralkyl and cycloalkyl;
I is an imino acyl or aliphatic amino acyl residue selected from the group consisting of L-prolyl, L-pipecolyl, 3-(loweralkyl)-prolyl, N-methyl-L-alanyl, N-methyl-norvalyl, 1-dihydroisoindole-2-L-carbonyl and thiazolidine-5-L-carbonyl; and

J is 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, or an amino acyl residue selected from D-alanylamine, L-alanylamine, sarcosylamine, N-(R_{40})-D-alanylamine, N-(R_{40})-L-alanylamine, N-(R_{40})-beta-L-alanylamine, N-(R_{40})-beta-D-alanylamine, L-2-aminobutyrylamine, D-2-aminobutyrylamine, N-(R_{40})-L-2-aminobutyrylamine, N-(R_{40})-D-2-aminobutyrylamine, L-serylamine, D-serylamine, N-(R_{40})-L-serylamine, N-(R_{40})-D-serylamine, N-(R_{40})-L-norvalylamine, N-(R_{40})-D-norvalylamine, L-norvalylamine, D-norvalylamine, wherein R_{40} is methyl,

ethyl, propyl or isopropyl; or J is $-NHR_8$ or $-NHCH_2CONHR_8$ wherein R_8 is hydrogen, loweralkyl, cycloalkyl, fluoro substituted loweralkyl or hydroxy substituted loweralkyl; or J is $-NHNH-C(O)-NH-R_{13}$ wherein R_{13} is hydrogen, loweralkyl, cycloalkyl, hydroxy substituted loweralkyl or fluoro substituted loweralkyl; with the proviso that the amide bond between at least one of the pairs of residues A-B, B-C, C-D, D-E, E-F, F-G, G-H, H-I, or I-J is alkylated on the nitrogen atom and with the proviso that the compound is not (pyro)Glu-His-Trp-Ser-Tyr-Gly-N-Me-Leu-Arg-Pro-Gly-NH₂, (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-N-Me-Leu-Arg-Pro-Gly-NH₂, (pyro)Glu-His-Trp-Ser-Tyr-Gly-N-Me-Leu-Arg-Pro-NH₂, or (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-N-Me-Leu-Arg-Pro-NH₂.

2. A compound of the formula:

A-B-C-D-E-F-G-H-I-J
1 2 3 4 5 6 7 8 9 10

or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable salt thereof; wherein A is an amino acyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acetyl-L-prolyl, N-acetyl-D-prolyl, N-acetyl-L- $\Delta^{3,4}$ -prolyl, N-acetyl-D- $\Delta^{3,4}$ -prolyl, N-acetyl-L-phenylalanyl, N-acetyl-D-phenylalanyl, N-acetyl-L-3-4-chlorophenylalanyl, N-acetyl-D-3-4-chlorophenylalanyl, N-acetyl-L-3-4-fluorophenylalanyl, N-acetyl-D-3-4-fluorophenylalanyl, N-acetyl-L-3-2-naphthylalanyl, N-acetyl-D-3-2-naphthylalanyl, N-acetyl-L-3-4-chlorophenylalanyl, N-acetyl-alpha-methyl-D-3-4-chlorophenylalanyl, N-acetyl-L-tyrosyl, N-acetyl-D-4-trifluoromethylphenylalanyl, N-acetyl-D-3-4-trifluoromethylphenylalanyl, N-acetyl-L-tyrosyl, N-acetyl-D-tyrosyl, N-acetyl-L-O-methyl-tyrosyl, N-acetyl-D-O-methyl-tyrosyl, N-acetyl-D-3-2-naphthylalanyl, N-acetyl-L-3-1-naphthylalanyl, N-acetyl-3-1-naphthylalanyl, N-acetylsarcosyl, N-acetyl-glycyl, L-N-acetyl-N-methylalanyl, N-acetyl-N-methyl-D-alanyl, N-acetyl-alpha-methyl-L-phenylalanyl, N-acetyl-alpha-methyl-D-phenylalanyl, N-formyl-N-methyl-L-alanyl, N-formyl-N-methyl-D-alanyl, N-acetyl-D-phenylalanyl, N-acetyl-L-phenylalanyl, N-formylsarcosyl, N-formyl-N-methyl-L-alanyl, N-formyl-N-methyl-D-alanyl, methylalanyl, 2-N-(ethylaminocarbonyl)-5-N-(ethylamido)glutamyl, N-delta-ethyl-glutamyl, L-prolyl, D-prolyl, L- $\Delta^{3,4}$ -prolyl, D- $\Delta^{3,4}$ -prolyl, L-phenylalanyl, D-phenylalanyl, L-3-4-chlorophenylalanyl, D-3-4-chlorophenylalanyl, L-3-4-fluorophenylalanyl, D-3-4-fluorophenylalanyl, alpha-methyl-L-3-4-chlorophenylalanyl, alpha-methyl-D-3-4-chlorophenylalanyl, L-3-4-trifluoromethylphenylalanyl, D-3-4-trifluoromethylphenylalanyl, L-tyrosyl, D-tyrosyl, L-O-methyl-tyrosyl, D-O-methyl-tyrosyl, sarcosyl, glycyl, L-N-methylalanyl, N-methyl-D-alanyl, alpha-methyl-L-phenylalanyl, alpha-methyl-D-phenylalanyl, D-phenylalanyl, and L-phenylalanyl;


phenylalanyl, and L-phenylalanyl;
B is absent or an amino acyl residue selected from the group consisting of L-histidyl, D-histidyl, L-phenylalanyl, D-phenylalanyl, L-3-(2-naphthyl)-alanyl, D-3-(2-naphthyl)-alanyl, L-3-(1-naphthyl)-alanyl, D-3-(1-naphthyl)-alanyl, L-3-(3-pyridyl)-alanyl, L-3-(2-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(4-fluorophenyl)alanyl, D-3-(4-fluorophenyl)alanyl, L-3-(4-chlorophenyl)alanyl, D-3-(4-chlorophenyl)alanyl, L-3-(4-fluorophenyl)alanyl, D-3-(4-fluorophenyl)alanyl, L-alpha-methyl-3-(4-chlorophenyl)alanyl, D-alpha-methyl-3-(4-chlorophenyl)alanyl, (3R)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl, (2N-(3S)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl, L-3-(2-pyridyl)-alanyl, D-3-(2-pyridyl)-alanyl, L-3-(3-ethylaminocarbonyl)-(5)-N-(ethylamido)glutanyl, L-3-(3-quinolyl)-alanyl, D-3-(3-quinolyl)-alanyl, N-(R₃₁)-L-phenylalanyl, pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(3-quinolyl)-alanyl, N-(R₃₁)-L-phenylalanyl, N-(R₃₁)-D-3-4-chlorophenylalanyl, N-(R₃₁)-L-3-4-chlorophenylalanyl, N-(R₃₁)-D-3-4-fluorophenylalanyl, N-(R₃₁)-L-3-4-fluorophenylalanyl, N-(R₃₁)-L-3-4-trifluoromethylphenylalanyl, N-(R₃₁)-D-3-4-trifluoromethylphenylalanyl, N-(R₃₁)-L-O-methyltyrosyl, N-(R₃₁)-L-tyrosyl, N-(R₃₁)-D-O-methyl-tyrosyl, N-(R₃₁)-D-tyrosyl, N-(R₃₁)-L-histidyl, N-(R₃₁)-D-histidyl, N-(R₃₁)-D-3-(2-naphthyl)-alanyl, N-(R₃₁)-L-3-(2-naphthyl)-alanyl, N-(R₃₁)-D-3-(1-naphthyl)-alanyl, and N-(R₃₁)-L-3-(1-naphthyl)-alanyl wherein R₃₁ is methyl, ethyl, propyl or isopropyl;

C is an amino acyl residue selected from the group consisting of L-tryptyl, D-tryptyl, L-phenylalanyl, D-phenylalanyl, alpha-methyl-L-phenylalanyl, alpha-methyl-D-phenylalanyl, L-3-1-naphthylalanyl, D-3-1-naphthylalanyl, L-O-methyltyrosyl, D-O-methyltyrosyl, L-3-4-chlorophenylalanyl, D-3-4-chlorophenylalanyl, alpha-methyl-L-3-4-chlorophenylalanyl, alpha-methyl-D-3-4-chlorophenylalanyl, L-3-4-trifluoromethylphenylalanyl, D-3-4-trifluoromethylphenylalanyl, L-3-(3-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(3-quinolyl)-alanyl, D-3-(3-quinolyl)-alanyl, L-3-(2-naphthyl)-alanyl, D-3-(2-naphthyl)-alanyl, N-(R₃₂)-D-phenylalanyl, N-(R₃₂)-L-phenylalanyl, N-(R₃₂)-D-tryptyl, N-(R₃₂)-L-tryptyl, N-(R₃₂)-D-3-4-fluorophenylalanyl, N-(R₃₂)-L-3-4-fluorophenylalanyl, N-(R₃₂)-D-3-4-chlorophenylalanyl, N-(R₃₂)-L-3-4-chlorophenylalanyl, N-(R₃₂)-L-3-4-fluorophenylalanyl, N-(R₃₂)-D-3-4-trifluoromethylphenylalanyl, N-(R₃₂)-D-3-(2-naphthyl)alanyl, N-(R₃₂)-L-3-(2-naphthyl)alanyl, N-(R₃₂)-D-3-(1-naphthyl)alanyl, N-(R₃₂)-L-3-(1-naphthyl)alanyl, N-(R₃₂)-O-methyl-D-tyrosyl and N-(R₃₂)-O-methyl-L-tyrosyl, wherein R₃₂ is methyl, ethyl, propyl or isopropyl;


D is an amino acyl residue selected from the group consisting of prolyl, L-seryl, O-benzyl-L-seryl, L-alanyl, L-threonyl, N-(R₀)-L-seryl, N-(R₀)-L-seryl(O-benzyl), N-(R₀)-L-alanyl, and N-(R₀)-L-threonyl, wherein R₀ is loweralkyl or allyl;

or D is -N(Et)CH₂CH(NHMe)C(O)-;

E is an amino acyl residue selected from the group consisting of L-tyrosyl, L-O-methyl-tyrosyl, L-phenylalanyl, N-(R₃₃)-L-tyrosyl, N-(R₃₃)-O-methyl-L-tyrosyl, N-(R₃₃)-L-phenylalanyl and N-(R₃₃)-O-ethyl-L-tyrosyl, wherein R₃₃ is methyl, ethyl, propyl or isopropyl; or E is




wherein n is 1 to 4; R₃₀ is methyl, ethyl propyl or isopropyl; and R₁ is




or -NHR₂ wherein R₂ is hydrogen, loweralkyl, cycloalkyl or R₂₀C(O)- wherein R₂₀ is a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R₂₀ is a substituted phenyl wherein the substituent is selected from methoxy, amino, alkylamino and dialkylamino; or R₁ is -NH(R₃)C(O)NH(R₄) or -NH(R₃)C(NH₂)=NR₄ wherein R₃ and R₄ are independently selected from hydrogen, loweralkyl and cycloalkyl;

F is a D-amino acyl residue of the formula:



wherein y is 1 to 3; R₅ is C₁ to C₆ straight or branched chain

alkyl, C₃ to C₆ cycloalkyl, phenyl, alkoxy, thioalkoxy, hydroxy, C₁ to C₆ straight or branched chain alkyl, C₃ to C₆ cycloalkyl, hydroxy, alkoxy, thioalkoxy, phenyl, 2-naphthyl, N-benzyl-4-imidazolyl, or a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R₅ is -(CH₂)_mR₆ wherein m is 1 to 4 and R₆ is -NH(R')C(O)NH(R'') or -NH(R')C(NH₂)=NR'' wherein R' and R'' are independently selected from hydrogen, loweralkyl and cycloalkyl; or R₆ is



or -NHR₇ wherein R₇ is hydrogen, loweralkyl, cycloalkyl or R₆ is R₂₁C(O)- wherein R₂₁ is a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic


aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R_{21} is a substituted phenyl wherein the substituent is selected from methoxy, amino, alkylamino and dialkylamino; R_{34} is methyl, ethyl, propyl or isopropyl; and R_{35} and R_{36} are independently selected from hydrogen and loweralkyl; or F is $R_{37}C(O)(CH_2)_zC(O)-$ wherein z is 1 to 3 and R_{37} is hydroxy,

5 alkoxy, phenoxy, amino or p-methoxyphenyl;

G is an amino acyl residue selected from the group consisting of L-leucyl, L-isoleucyl, N-(R_{38})-isoleucyl, norleucyl, N-(R_{38})-norleucyl, L-N-(R_{38})-leucyl, alloisoleucyl, valyl, norvalyl, tyrosyl, tryptyl, 2-aminobutyryl, (cyclohexyl)-L-alanyl, N-(R_{38})-L-cyclohexylalanyl, N-(R_{38})-valyl, phenylalanyl, N-(R_{38})-phenylalanyl, N-(R_{38})-tryptyl, N-(R_{38})-tyrosyl, prolyl, pipecolyl, seryl and N-(R_{38})-seryl, wherein R_{38} is methyl, ethyl, propyl or


10 isopropyl; or

F and G taken together are




wherein R_{47} is hydrogen, loweralkyl, 3-indolylmethyl, 2-naphthylmethyl, benzyl or substituted benzyl wherein the phenyl ring is substituted with a substituent selected from hydroxy and methoxy;

25 H is an amino acyl residue of the formula:



35 wherein p is 1 to 4; R_{39} is methyl, ethyl, propyl or isopropyl; and R_9 is



45 or -NHR₁₀ wherein R_{10} is hydrogen, loweralkyl, cycloalkyl or $R_{22}C(O)-$ wherein R_{22} is a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R_{22} is a substituted phenyl wherein the substituent is selected from methoxy, amino, alkylamino and dialkylamino; or R_9 is $-NH(R_{11})C(O)NH(R_{12})$ or $-NH(R_{11})C(NH_2)=NR_{12}$ wherein R_{11} and R_{12} are independently selected from hydrogen, loweralkyl and cycloalkyl;

50 I is an imino acyl or aliphatic amino acyl residue selected from the group consisting of L-prolyl, L-pipecolyl, 3-(loweralkyl)-prolyl, N-methyl-L-alanyl, N-methyl-norvalyl, 1-dihydroisoindole-2-L-carbonyl and thiazolidine-5-L-carbonyl; and

J is 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, or an amino acyl residue selected from D-alanylamine, L-alanylamine, sarcosylamine, N-(R_{40})-D-alanylamine, N-(R_{40})-beta-L-alanylamine, N-(R_{40})-beta-D-alanylamine, L-2-aminobutyrylamine, D-2-aminobutyrylamine, N-(R_{40})-L-2-aminobutyrylamine, N-(R_{40})-D-2-aminobutyrylamine, L-serylamine, D-serylamine, N-(R_{40})-L-serylamine, N-(R_{40})-D-serylamine, N-(R_{40})-L-norvalylamine, N-(R_{40})-D-norvalylamine, L-norvalylamine, D-norvalylamine, wherein R_{40} is methyl, ethyl, propyl or isopropyl; or J is $-NHR_8$ or $-NHCH_2CONHR_8$ wherein R_8 is hydrogen, loweralkyl, cycloalkyl,

fluoro substituted loweralkyl or hydroxy substituted loweralkyl; or J is -NHNH-C(O)-NH-R₁₃ wherein R₁₃ is hydrogen, loweralkyl, cycloalkyl, hydroxy substituted loweralkyl or fluoro substituted loweralkyl; with the proviso that the amide bond between at least one of the pairs of residues A-B, B-C, C-D, D-E, E-F, F-G, G-H, H-I, or I-J is alkylated on the nitrogen atom and with the proviso that the compound is not

- 5 (pyro)Glu-His-Trp-Ser-Tyr-Gly-N-Me-Leu-Arg-Pro-Gly-NH₂, (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-N-Me-Leu-Arg-Pro-Gly-NH₂, (pyro)Glu-His-Trp-Ser-Tyr-Gly-N-Me-Leu-Arg-Pro-NH₂, or (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-N-Me-Leu-Arg-Pro-NH₂.

3. The compound of Claim 2 wherein A is N-acetylsarcosyl, (pyro)-L-glutamyl, (2)-N-(ethylaminocarbonyl)-(5)-N-ethylamidoglutamyl, L-N-acetylprolyl, N-acetyl-D-3-2-naphthylalanyl, N-acetyl-L-3-2-naphthylalanyl, N-acetyl-D-3-1-naphthylalanyl, L-N-acetyl-N-methylalanyl, N-acetyl-L-prolyl, N-acetyl-D-3-4-fluorophenylalanyl, N-acetyl-L-delta^{3,4}-prolyl or N-acetyl-D-3-4-chlorophenylalanyl;

B is L-histidyl, L-phenylalanyl, D-3-4-fluorophenylalanyl, D-3-phenylalanyl, D-3-2-naphthylalanyl, D-3-2-pyridylalanyl, N-methyl-L-phenylalanyl, N-methyl-D-phenylalanyl, N-methyl-L-histidyl, N-methyl-D-3-4-chlorophenylalanyl, N-methyl-3-4-fluorophenylalanyl or D-3-4-chlorophenylalanyl;

15 C is L-tryptyl, D-tryptyl, D-3-3pyridylalanyl, N-methyl-D-3-3pyridylalanyl, d-1-naphthylalanyl, D-4-chlorophenylalanyl, L-4-chlorophenylalanyl, N-methyl-1-naphthylalanyl, N-methyl-tryptyl, N-methyl-3-4-chlorophenylalanyl, N-methyl-O-methyltyrosyl or L-O-methyltyrosyl;

D is N-methyl-L-seryl, N-methyl-alanyl, N-methyl-threonyl, N-methyl-seryl(O-benzyl), seryl, threonyl, alanyl, seryl(O-benzyl) or (2)-N-Me-(3)-N-Et 2,3-diaminopropionyl;

20 E is tyrosyl, N-methyltyrosyl, phenylalanyl, lysyl(N-epsilon-nicotinoyl) or N-methyl-lysyl(N-epsilon-nicotinoyl);

F is D-leucyl, D-lysyl(N-epsilon-nicotinoyl), D-tryptyl, D-seryl(O-t-butyl), D-2-naphthylalanyl, D-(epsilon)-lysyl(N-epsilon-isp), N-methyl-D-seryl(O-t-butyl), D-tyrosyl, D-seryl, N-methyl-D-leucyl, N-methyl-D-tryptyl, N-methyl-D-2-naphthylalanyl, N-methyl-D-lysyl(N-epsilon-nicotinoyl or D-cyclohexylalanyl);

25 G is L-leucyl, L-N-methylleucyl, N-methyl-cyclohexylalanyl or L-cyclohexylalanyl; or F and G taken together is 2-(S-3-amino-2-oxo-pyrrolidin-1-yl)-S-2-isopropylmethylacetate;

H is L-arginyl, N-methylarginyl, lysyl(N-epsilon-isopropyl) or N-methyl-lysyl(N-epsilon-isopropyl);

I is L-prolyl, L-pipecolyl or N-methyl-L-alanyl; and

J is N-ethyl, glycylamide, azaglycylamide or D-alanylamide.

30 4. A method for increasing or suppressing levels of sex hormones in male or female mammals comprising administering to a host in need of such treatment a therapeutically effective amount of an LHRH agonist compound of Claim 1.

5. A method for suppressing levels of sex hormones in male or female mammals comprising administering to a host in need of such treatment a therapeutically effective amount of an LHRH antagonist compound of Claim 1.

35 6. A pharmaceutical composition for increasing or suppressing levels of sex hormones in male or female mammals, comprising a pharmaceutical carrier and a therapeutically effective amount of an LHRH agonist compound of Claim 1.

7. A pharmaceutical composition for suppressing levels of sex hormones in male or female mammals, 40 comprising a pharmaceutical carrier and a therapeutically effective amount of an LHRH antagonist compound of Claim 1.

8. A process for the preparation of a compound of the formula:



45

1 2 3 4 5 6 7 8 9 10

or a pharmaceutically acceptable salt thereof;

50 wherein A is an amino acyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acetyl-L-prolyl, N-acetyl-D-prolyl, N-acetyl-L-delta^{3,4}-prolyl, N-acetyl-D-delta^{3,4}-prolyl, N-acetyl-L-phenylalanyl, N-acetyl-D-phenylalanyl, N-acetyl-L-3-4-chlorophenylalanyl, N-acetyl-D-3-4-chlorophenylalanyl, N-acetyl-L-3-4-fluorophenylalanyl, N-acetyl-D-3-4-fluorophenylalanyl, N-acetyl-L-3-2-naphthylalanyl, N-acetyl-alpha-methyl-L-3-4-chlorophenylalanyl, N-acetyl-alpha-methyl-D-3-4-chlorophenylalanyl, N-acetyl-L-3-4-trifluoromethylphenylalanyl, N-acetyl-D-3-4-trifluoromethylphenylalanyl, N-acetyl-L-tyrosyl, N-acetyl-D-tyrosyl, N-acetyl-L-O-methyl-tyrosyl, N-acetyl-D-O-methyl-tyrosyl, N-acetyl-D-3-2-naphthylalanyl, N-acetyl-L-3-1-naphthylalanyl, N-acetyl-3-1-naphthylalanyl, N-acetylsarcosyl, N-acetyl-glycyl, L-N-acetyl-N-methylalanyl, N-acetyl-N-methyl-D-alanyl, N-acetyl-alpha-methyl-L-phenylalanyl, N-acetyl-alpha-methyl-D-phenylalanyl, N-

acetyl-D-phenylalanyl, N-acetyl-L-phenylalanyl, N-formylsarcosyl, N-formyl-N-methyl-L-alanyl, N-formyl-N-methylalanyl, 2-N-(ethylaminocarbonyl)-5-N-(ethylamido)glutamyl, N-delta-ethyl-glutamyl, L-prolyl, D-prolyl, L-delta^{3,4}-prolyl, D-delta^{3,4}-prolyl, L-phenylalanyl, D-phenylalanyl, L-3-4-chlorophenylalanyl, D-3-4-chlorophenylalanyl, L-3-4-fluorophenylalanyl, D-3-4-fluorophenylalanyl, alpha-methyl-L-3-4-chlorophenylalanyl, alpha-methyl-D-3-4-chlorophenylalanyl, L-3-4-trifluoromethylphenylalanyl, D-3-4-trifluoromethylphenylalanyl, L-tyrosyl, D-tyrosyl, L-O-methyl-tyrosyl, D-O-methyl-tyrosyl, sarcosyl, Glycyl, L-N-methylalanyl, N-methyl-D-alanyl, alpha-methyl-L-phenylalanyl, alpha-methyl-D-phenylalanyl, D-phenylalanyl, and L-phenylalanyl;


B is absent or an amino acyl residue selected from the group consisting of L-histidyl, D-histidyl, L-phenylalanyl, D-phenylalanyl, L-3-(2-naphthyl)-alanyl, D-3-(2-naphthyl)-alanyl, L-3-(1-naphthyl)-alanyl, D-3-(1-naphthyl)-alanyl, L-3-(3-pyridyl)-alanyl, L-3-(2-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(3-pyrazolyl)-alanyl, D-3-(3-pyrazolyl)-alanyl, L-3-(4-chlorophenyl)alanyl, D-3-(4-chlorophenyl)alanyl, L-3-(4-fluorophenyl)alanyl, D-3-(4-fluorophenyl)alanyl, L-alpha-methyl-3-(4-chlorophenyl)alanyl, D-alpha-methyl-3-(4-chlorophenyl)alanyl, (3S)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl, (3R)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl, (2)-N-(ethylaminocarbonyl)-(5)-N-(ethylamido)glutamyl, L-3-(2-pyridyl)-alanyl, D-3-(2-pyridyl)-alanyl, L-3-(3-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(3-quinolyl)-alanyl, D-3-(3-quinolyl)-alanyl, N-(R₃₁)-L-phenylalanyl, N-(R₃₁)-D-phenylalanyl, N-(R₃₁)-D-3-4-chlorophenylalanyl, N-(R₃₁)-L-3-4-chlorophenylalanyl, N-(R₃₁)-D-3-4-fluorophenylalanyl, N-(R₃₁)-L-3-4-fluorophenylalanyl, N-(R₃₁)-L-3-4-trifluoromethylphenylalanyl, N-(R₃₁)-D-3-4-trifluoromethylphenylalanyl, N-(R₃₁)-L-O-methyltyrosyl, N-(R₃₁)-D-O-methyltyrosyl, N-(R₃₁)-L-tyrosyl, N-(R₃₁)-D-tyrosyl, N-(R₃₁)-L-histidyl, N-(R₃₁)-D-histidyl, N-(R₃₁)-D-3-(2-naphthyl)-alanyl, N-(R₃₁)-L-3-(2-naphthyl)-alanyl, N-(R₃₁)-D-3-(1-naphthyl)-alanyl, and N-(R₃₁)-L-3-(1-naphthyl)-alanyl, wherein R₃₁ is methyl, ethyl, propyl or isopropyl;

C is an amino acyl residue selected from the group consisting of L-tryptyl, D-tryptyl, L-phenylalanyl, D-phenylalanyl, alpha-methyl-L-phenylalanyl, alpha-methyl-D-phenylalanyl, L-3-1-naphthylalanyl, D-3-1-naphthylalanyl, L-O-methyltyrosyl, D-O-methyltyrosyl, L-3-4-chlorophenylalanyl, D-3-4-chlorophenylalanyl, alpha-methyl-L-3-4-chlorophenylalanyl, alpha-methyl-D-3-4-chlorophenylalanyl, L-3-4-trifluoromethylphenylalanyl, D-3-4-trifluoromethylphenylalanyl, L-3-(3-pyridyl)-alanyl, D-3-(3-pyridyl)-alanyl, L-3-(3-quinolyl)-alanyl, D-3-(3-quinolyl)-alanyl, L-3-(2-naphthyl)-alanyl, D-3-(2-naphthyl)-alanyl, N-(R₃₂)-D-phenylalanyl, N-(R₃₂)-L-phenylalanyl, N-(R₃₂)-D-tryptyl, N-(R₃₂)-L-tryptyl, N-(R₃₂)-D-3-4-fluorophenylalanyl, N-(R₃₂)-L-3-4-fluorophenylalanyl, N-(R₃₂)-D-3-4-chlorophenylalanyl, N-(R₃₂)-L-3-4-chlorophenylalanyl, N-(R₃₂)-L-3-4-trifluoromethylphenylalanyl, N-(R₃₂)-D-3-4-trifluoromethylphenylalanyl, N-(R₃₂)-D-3-(2-naphthyl)alanyl, N-(R₃₂)-L-3-(2-naphthyl)alanyl, N-(R₃₂)-D-3-(1-naphthyl)alanyl, N-(R₃₂)-L-3-(1-naphthyl)alanyl, N-(R₃₂)-O-methyl-D-tyrosyl and N-(R₃₂)-O-methyl-L-tyrosyl, wherein R₃₂ is methyl, ethyl, propyl or isopropyl;


D is an amino acyl residue selected from the group consisting of prolyl, L-seryl, O-benzyl-L-seryl, L-alanyl, L-threonyl, N-(R₀)-L-seryl, N-(R₀)-L-seryl(O-benzyl), N-(R₀)-L-alanyl, and N-(R₀)-L-threonyl wherein R₀ is loweralkyl or allyl;

or D is -N(Et)CH₂CH(NHMe)C(O)-;

E is an amino acyl residue selected from the group consisting of L-tyrosyl, L-O-methyl-tyrosyl, L-phenylalanyl, N-(R₃₃)-L-tyrosyl, N-(R₃₃)-O-methyl-L-tyrosyl, N-(R₃₃)-L-phenylalanyl and N-(R₃₃)-O-ethyl-L-tyrosyl, wherein R₃₃ is methyl, ethyl, propyl or isopropyl; or E is



50 wherein n is 1 to 4; R₃₀ is methyl, ethyl propyl or isopropyl; and R₁ is




or -NHR₂ wherein R₂ is hydrogen, loweralkyl, cycloalkyl or R₂₀C(O)- wherein R₂₀ is a heterocyclic aromatic

ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R_{20} is a substituted phenyl wherein the substituent is selected from methoxy, amino, alkylamino and dialkylamino; or R_1 is $-\text{NH}(R_3)\text{C}(\text{O})\text{NH}(R_4)$ or $-\text{NH}(R_3)\text{C}(\text{NH}_2)=\text{NR}_4$ wherein R_3 and R_4 are independently selected from hydrogen, loweralkyl and cycloalkyl;

F is a D-amino acyl residue derived from any of the naturally occurring alpha-amino acids or from synthetic, non-natural alpha-amino acids;


G is an amino acyl residue selected from the group consisting of L-leucyl, L-isoleucyl, N-(R_{38})-isoleucyl, norleucyl, N-(R_{38})-norleucyl, L-N-(R_{38})leucyl, alloisoleucyl, valyl, norvalyl, tyrosyl, tryptyl, 2-aminobutyryl, (cyclohexyl)-L-alanyl, N-(R_{38})-L-cyclohexylalanyl, N-(R_{38})-valyl, phenylalanyl, N-(R_{38})-phenylalanyl, N-(R_{38})-tryptyl, N-(R_{38})-tyrosyl, prolyl, pipecolyl, seryl and N-(R_{38})-seryl, wherein R_{38} is methyl, ethyl, propyl or isopropyl; or

F and G taken together are




wherein R_{47} is hydrogen, loweralkyl, 3-indolylmethyl, 2-naphthylmethyl, benzyl or substituted benzyl wherein the phenyl ring is substituted with a substituent selected from hydroxy and methoxy;

H is an amino acyl residue of the formula:



wherein p is 1 to 4; R_{39} is methyl, ethyl, propyl or isopropyl; and R_9 is



or $-\text{NHR}_{10}$ wherein R_{10} is hydrogen, loweralkyl, cycloalkyl or $R_{22}\text{C}(\text{O})-$ wherein R_{22} is a heterocyclic aromatic ring system of one ring or two fused rings, each ring having 5 or 6 atoms, and the heterocyclic aromatic ring system having one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; or R_{22} is a substituted phenyl wherein the substituent is selected from methoxy, amino, alkylamino and dialkylamino; or R_9 is $-\text{NH}(R_{11})\text{C}(\text{O})\text{NH}(R_{12})$ or $-\text{NH}(R_{11})\text{C}(\text{NH}_2)=\text{NR}_{12}$ wherein R_{11} and R_{12} are independently selected from hydrogen, loweralkyl and cycloalkyl;

I is an imino acyl or aliphatic amino acyl residue selected from the group consisting of L-prolyl, L-pipecolyl, 3-(loweralkyl)-prolyl, N-methyl-L-alanyl, N-methyl-norvalyl, 1-dihydroisoindole-2-L-carbonyl and thiazolidine-5-L-carbonyl; and

J is 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, or an amino acyl residue selected from D-alanylamine, L-alanylamine, sarcosylamine, N-(R_{40})-D-alanylamine, N-(R_{40})-L-alanylamine, N-(R_{40})-beta-L-alanylamine, N-(R_{40})-beta-D-alanylamine, L-2-aminobutyrylamine, D-2-aminobutyrylamine, N-(R_{40})-L-2-aminobutyrylamine, N-(R_{40})-D-2-aminobutyrylamine, L-serylamine, D-serylamine, N-(R_{40})-L-serylamine, N-(R_{40})-D-serylamine,

- N-(R₄₀)-L-norvalylamide, N-(R₄₀)-D-norvalylamide, L-norvalylamide, D-norvalylamide, wherein R₄₀ is methyl, ethyl, propyl or isopropyl; or J is -NHR₈ or -NHCH₂CONHR₈ wherein R₈ is hydrogen, loweralkyl, cycloalkyl, fluoro substituted loweralkyl or hydroxy substituted loweralkyl; or J is -NHNH-C(O)-NH-R₁₃ wherein R₁₃ is hydrogen, loweralkyl, cycloalkyl, hydroxy substituted loweralkyl or fluoro substituted loweralkyl; with the proviso that the amide bond between at least one of the pairs of residues A-B, B-C, C-D, D-E, E-F, F-G, G-H, H-I, or I-J is alkylated on the nitrogen atom and with the proviso that the compound is not (pyro)Glu-His-Trp-Ser-Tyr-Gly-N-Me-Leu-Arg-Pro-Gly-NH₂, (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-N-Me-Leu-Arg-Pro-Gly-NH₂, (pyro)Glu-His-Trp-Ser-Tyr-Gly-N-Me-Leu-Arg-Pro-NH₂, or (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-N-Me-Leu-Arg-Pro-NH₂, comprising sequentially coupling suitably protected amino acids or amino acid analogs, followed by removal of the protecting groups.
9. The process of Claim 8 wherein sequences of two or more suitably protected amino acids or amino acid analogs are coupled and the resulting peptides are coupled, followed by removal of the protecting groups, to provide the desired product.

15

20

25

30


35

40


45

50

55



INTESTINAL STABILITY OF LHRH ANALOGS RAT JEJUNUM, IN VITRO



Neu eingereicht / Newly filed
 Nouvellement déposé

THIS PAGE BLANK (USPTO)

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 328 090
A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 89102208.9

(51) Int. Cl.⁵: **C07K 7/20, A61K 37/43,**
//C07K99:56, C07K99:54

(22) Date of filing: 09.02.89

(30) Priority: 10.02.88 US 154681

(43) Date of publication of application:
16.08.89 Bulletin 89/33

(84) Designated Contracting States:
ES GR

(88) Date of deferred publication of the search report:
16.08.90 Bulletin 90/33

(71) Applicant: ABBOTT LABORATORIES

Abbott Park Illinois 60064(US)

(72) Inventor: Haviv, Fortuna
1125 Oxford Road
Deerfield, IL 60015(US)
Inventor: Greer, Jonathan
6757 N. Sacramento Avenue
Chicago, IL 60645(US)


(74) Representative: Modiano, Guido et al
MODIANO, JOSIF, PISANTY & STAUB
Modiano & Associati Via Meravigli, 16
I-20123 Milano(IT)

(54) LHRH analogs.

(57) The present invention relates to novel "pseudo"
nonapeptide and decapeptide derivatives of LHRH.
More particularly the present invention relates to

derivatives of LHRH wherein the nitrogen atom of at
least one of the amide bonds has been alkylated.

INTESTINAL STABILITY OF LHRH ANALOGS
RAT JEJUNUM, IN VITRO



EP 0 328 090 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT
which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

Application number
EP 89 10 2208

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X,Y	GB-A-2 009 182 (THE SALK INSTITUTE) * Page 2, lines 8-13; example 1; claims 1,3,4,8,27-29 *	1-3, 6-9	C 07 K 7/20 A 61 K 37/43
	--		
X,Y	J. MED. CHEM., vol. 25, 1982, - pages 795-801, American Chemical Society; J.J. NESTOR et al.: "Synthesis and biological activity of some very hydrophobic superagonist analogues of luteinizing hormone-releasing hormone" * Page 795, column 1 - page 796, column 1; page 798, column 2; table III *	1-3, 6-9	
	--		
	./.		
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			C 07 K A 61 K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely: Claims searched incompletely: Claims not searched: 4,5 Reason for the limitation of the search:</p> <p>Method for treatment of the human or animal body by surgery or therapy (see Art. 52(4) of the European Patent Convention).</p>			
Place of search THE HAGUE		Date of completion of the search 09-05-1990	Examiner GROENENDIJK
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X,Y	ENDOCRINE REVIEWS, vol. 7, no. 1, 1986, pages 44-66; The Endocrine Society, US; M.J. KARTEN et al.: "Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective" * Page 46, column 1; page 48, columns 1-2 *	1-3, 6-9	
	--		
X,Y	EP-A-0 021 234 (SYNTEX INC) * Page 3, lines 5-8; examples 4,5,9; claims 1,2,5,7,11,12 *	1-3, 6-9	TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
	--		
Y	J. MED. CHEM., vol. 29, 1986, pages 2088-2093, American Chemical Society; S. THAISRIVONGS et al.: "Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo" * Page 2089, column 1 - page 2091, column 1 *	1-3, 6-9	
	--		
E	EP-A-0 328 089 (ABBOTT LAB.) * Claims 1-3,7-10 *	1,2,6-9	

THIS PAGE BLANK (USPTO)